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ABSTRACT 
 Topoisomerase 2 (TOP2) performs a vital enzymatic activity, solving DNA 
topological problems in fundamental metabolic processes. The enzyme is able to 
untangle DNA by passing an intact helix through a transient double-strand break 
(DSB). The intermediate of its catalytic cycle, TOP2 covalently bound to DNA, is 
usually short lived, and is known as the TOP2 cleavage complex (TOP2cc). 
However, TOP2cc can be stabilized upon collision with the transcription or 
replication machinery, or upon the addition of TOP2 poisons, such as etoposide, 
which prevent religation of the transiently cleaved DNA. Stabilized TOP2 trapped 
in these cleavage complexes is degraded by the proteasome, leaving a small peptide 
still covalently bound to the DNA. Tyrosyl-DNA phosphodiesterase 2 (TDP2) is a 
protein involved in the removal of proteasome degraded TOP2cc, thus important for 
the efficient repair of TOP2-induced DNA DSBs. Consequently, TDP2-deficient 
cells are sensitive to etoposide. We report an additional function of TDP2, able to 
remove full-length undegraded TOP2 from covalent complexes.  
 Sumoylation is an important modification involved in the DNA damage 
response (DDR). While TOP2 sumoylation is important in several cellular 
processes, it was not known whether TOP2 is sumoylated in the context of the 
cleavage complex and its possible physiological relevance. In this work, we 
describe for the first time SUMO1 and SUMO2/3 modification of TOP2cc, with 
TDP2 being able to remove such structures. We imply a role for the novel TDP2 
split-SIM (SUMO interacting surface) in the preferential removal of SUMO 
modified TOP2cc. With a physical proximity screen, we identify the SUMO E3 
ligase ZNF451 as a novel factor involved in TOP2cc metabolism, which together 
with TDP2 is involved in a novel pathway for the repair of TOP2cc independent of 
known proteasomal pathways.  
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INTRODUCTION 
1. DNA Topoisomerases 
 “Since the two chains in our model are intertwined, it is essential for them to 
untwist if they are to separate […] Although it is difficult at the moment to see how 
these processes occur without everything getting tangled, we do not feel that this 
objection will be insuperable.” 
-J.D. Watson and F.H.C. Crick, 1953 
 
 The story of topoisomerases, the enzymes known as topological problem 
solvers, begins with the description of the necessity of their function, derived from 
the double-helical structure of DNA and its compaction inside the nucleus. At the 
very beginning of the discovery of the structure of DNA, Watson and Crick 
recognized that the cell certainly had to have mechanisms to allow accessing the 
information stored in DNA without it getting all tangled up in the process (Watson 
& Crick, 1953). It would take almost 20 more years for the first validation of this 
theory, and, to date, we are still learning more about the intricacy of topoisomerases 
and their involvement in an increasing number of cellular processes (Seol & 
Neuman, 2016; McKinnon, 2016; Ashour et al., 2015; Nitiss, 2009b; Deweese, 
2009; Champoux, 2001). 
 James C. Wang, a pioneer in the field, proposed in 1971 that DNA topo-
isomerization is catalyzed by an enzyme that forms bond with DNA, and purified 
the first known member of the topoisomerase family from Escherichia coli extracts, 
protein ω (omega) (later known to be topoisomerase 1 (TOP1)), able to relax 
negatively supercoiled DNA (Wang et al., 1971). Depew and Wang detected the 
formation of a complex between TOP1 and single-stranded DNA, and presented 
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evidence that the protein is able to create transient breaks in the DNA backbone 
(Depew et al., 1978). Wang proposed the term topoisomerase in 1979 (Liu & Wang, 
1979). 
TOP2 is involved in various processes in which access to the DNA is 
needed. Such processes that involve strand unwinding create a topological problem 
in the form of compensatory “overwinding” in a different location in the DNA 
molecule, which can’t be solved by simple rotation due to the large size of the 
eukaryotic chromosome.  
From bacteria to higher eukaryotes, all topoisomerases have a common 
mechanism of action, which involves creating a transient break in DNA to manage 
the topological state (Champoux, 2001). There are two main classes of topoisomer-
ases, type I and type II, which differ in how many DNA strands of a duplex are cut 
during a catalytic cycle. Type I topoisomerases cleave only one DNA strand. Within 
type I are type IA, in which the protein links to a 5’phosphate of the DNA during its 
catalytic cycle, such as bacterial TOP1, and type IB, with the protein attaching to a 
3’phosphate. All higher eukaryotes and yeast have TOP1, a type IB enzyme, which 
has important roles in aiding with replication fork movement and transcription-
related supercoil resolution, and is indispensable in development (Lee et al., 1993) 
(see Table 1 for a list of human topoisomerases). Mitochondrial TOP1mt, a paralog 
of nuclear TOP1, is also a type IB enzyme, specific for the replication of 
mitochondrial DNA in vertebrates (Rosa et al., 2009). Two isoforms of 
topoisomerase 3 (TOP3) are also present in higher eukaryotes, TOP3α and TOP3β, 
which are type IA. Whereas type IA enzymes employ a single-stranded passage 
mechanism, type IB topoisomerases use a swivelase mechanism, involving DNA 
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end rotation (Koster et al., 2005).  
While type I enzymes can modulate over- and underwinding, they have the 
limitation of not being able to remove knots and tangles from duplex DNA. On the 
other hand, type II enzymes, which cleave both DNA strands, are able to remove 
such structures. Type II topoisomerases also include type IIA and IIB, both with a 
strand passage mechanism. While eukaryotes lack type canonical IIB 
topoisomerases, a type IIB related enzyme necessary for meiotic recombination, 
Spo11, is present. One form of type IIA topoisomerase 2 (TOP2) is in present in 
lower eukaryotes and invertebrates, while higher eukaryotes have two TOP2 
paralogs, which are 170 kDa topoisomerase 2α (TOP2α) and 180 kDa topoiso-
merase 2β (TOP2β) in mammals (Drake et al., 1989). They share around 77% 
sequence homology but differ in the C-terminal regions (Linka et al., 2007). Due to 
the C-terminal differences, TOP2α has a preference for relaxing positive supercoils, 
while TOP2β does not seem to have a supercoiling preference (McClendon et al., 
2005). The C-terminal differences between TOP2α and TOP2β may correspond to 
differences in cellular function.  
The TOP2α isoform is essential in all cells, and TOP2α protein levels peak 
at G2/M phase of cell cycle (Woessner et al., 1991). TOP2α is essential for DNA 
decatenation, chromosome condensation and disjunction (Grue et al., 1998). 
Although required for normal mammalian development, in some cell lines TOP2β is 
not expressed, and is dispensable for proliferation and survival in vitro (Chen & 
Beck, 1995). However, it is the main topoisomerase 2 activity in differentiated cells. 
TOP2β was discovered to be involved in an early stage of granule cell 
differentiation (Tsutsui et al., 2001).  During the process of replication, the two 
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strands of the double helix are permanently separated. Eukaryotic TOP2, 
redundantly with TOP1, can remove overwinding causing positive supercoiling  in 
front of the replication machinery (Figure I1a) (Brill et al., 1987; Deweese & 
Figure I1. Nuclear processes affect DNA topology. DNA replication and transcr iption are used 
as examples. DNA ends are attached to a hypothetical immobile structure, represented by red 
ellipses, and are unable to rotate. a. As the replication machinery (yellow) advances, turns ahead of it 
are compressed and the DNA cannot rapidly rotate, creating positive superhelical stress which forms 
positive supercoils ahead of the advancing fork. When the fork occasionally rotates with the turn of 
the DNA helix, precatenanes can form. If not resolved by topoisomerase action, fork progression can 
be impeded and precatenanes can lead to the formation of sister chromatid intertwinings (SCI). b. 
During transcription, as RNA polymerase (blue) advances, the DNA becomes overwound and forms 
positive supercoils. The DNA behind the replication bubble is underwound, and forms negative 
supercoils. While both TOP1 and TOP2 can remove positive and negative supercoils, only TOP2 can 
resolve SCI. This figure is based on Wang, 2002, Deweese & Osheroff, 2009, and Jeppsson et al., 
2014. 
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Osheroff, 2008). While replication fork rotation can alleviate some superhelical 
tension that builds up ahead of the progressing fork, it can bring about intertwinings 
of daughter duplexes (precatenanes) that rely solely on TOP2 to resolve them prior 
to separation and cell division (Pommier et al., 2016). Additionally, it has been 
observed that eukaryotic TOP2, along with TOP1, associates directly with specific 
replication origins to assist in activation (Abdurashidova et al., 2007).  
Another process in which topoisomerase action is needed is transcription 
(Figure I1b). As transcription proceeds, DNA ahead of the RNA polymerase 
becomes positively supercoiled, while the DNA behind it becomes negatively 
supercoiled and the DNA must be relaxed, by either TOP2 or TOP1 redundantly 
(Wu et al., 1988). In yeast, transcription elongation of long genes is aided by TOP2 
(Joshi et al., 2012). TOP2β seems to be the main mammalian TOP2 isoform 
responsible for removing torsional stress during transcription. Additionally, TOP2β 
cleavage has been implicated in the control of promoter activity during brain 
development, transcription of hormonally regulated genes, and activation of certain 
immediate early response genes (Ju et al., 2006; Pommier et al., 2016; Madahbushi 
et al., 2015). TOP2β  has even been linked to expression of long genes related to 
synaptic function and autism spectrum disorders (King et al., 2013). 
 
1.1. Topoisomerase 2 catalytic reaction 
The basic reaction tactic for TOP2 is the creation of a transient DNA double 
strand break (DSB), with each subunit of the homodimeric enzyme breaking one 
strand. An unbroken duplex is passed through the break, which is then resealed. 
TOP2 has three regions of protein interfaces, referred to as gates, which are the N-
 8 
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Figure I2. Type IIA topoisomerase action. Mechanism of action of type IIA topoisomerases, 
such as TOP2. TOP2 Binds the G segment (light blue and green), bending it. In the open clamp con-
formation, it waits for a second DNA segment. When the T segment (pink and purple) enters the N-
gate, the clamp closes, the G segment is broken. The TOP2cc is formed with a phosphotyrosine bond 
between each strand and a tyrosine in each TOP2 subunit. The DNA-gate is opened and the T seg-
ment passes through to the central cavity. Then, the DNA-gate closes and the G segment is religated. 
The exit C-gate opens to release the T segment. The G segment can either be released, or undergo an 
additional catalytic cycle.  
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gate, DNA-gate, and C-gate (Figure I2, bottom right). Historically, TOP2 has been 
described as having a two-gate mechanism, as described by Wang and colleagues 
(Roca et al., 1996). 
More specifically, as can be appreciated in (Figure I2, top middle), the TOP2 
active site opens up and binds the segment of DNA that later will be broken, which 
is designated the G or “gate segment,” which is then strongly bent. While in the 
open-clamp conformation, the enzyme waits for the second DNA segment, the T 
segment (“transfer segment”). Upon ATP binding, the enzyme undergoes a 
conformational change and forms a new protein-protein interface, the “N-gate,” 
which is in a closed clamp conformation that closes the active site, which may 
capture the T segment. In the presence of Mg2+, upon closure of the clamp, TOP2 
induces a DSB in the G segment, catalyzed by an active site tyrosine in each 
subunit. A phosphotyrosine linkage is formed between each tyrosine and a single 
strand of DNA, forming the covalently linked TOP2-DNA cleavage complex 
(TOP2cc), also known as the cleavable/covalent complex. This triggers a 
conformational change that opens a gap in the G segment and opens the DNA-gate, 
through which the enzyme passes the T segment, which moves to the central TOP2 
cavity. Once the DNA-gate closes, on religation of the G segment, the carboxyl 
terminus exit gate, “C-gate,” can open, releasing the T segment on the opposite side. 
ATP hydrolysis may assist in the strand passage, and a second hydrolysis allows 
clamp re-opening. The G segment can either be released or another catalytic cycle 
can initiate with the same G segment (Vologodskii, 2016; Nitiss, 2009b). 
The cleavage reaction is easily reversed because the energy is conserved in 
the form of the phosphotyrosyl bond, and ATP is not required for this reaction. The 
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ATP requirement of the TOP2 catalytic cycle is due to the unidirectional transfer of 
the T segment (Roca et al., 1996). Maxwell and co-workers suggest that the role of 
ATP hydrolysis could serve as protection against accidental DNA DSBs (Bates et 
al., 2011). Berger and colleagues stipulate that the ATPase domains pivot about 
each other to guarantee unidirectional strand passage (Schmidt et al., 2012). 
 
1.2. Topoisomerase inhibitors and poisons 
There are two categories of drugs that impact the catalytic activity of TOP2. 
The first, “catalytic inhibitors,” decrease the overall activity of the enzyme and kill 
cells by eliminating the essential activity of TOP2 (Nitiss, 2009a). TOP2 catalytic 
inhibitors are mostly nonspecific, except for the bisdioxopiperazines, which include 
ICRF-187 and ICRF-193.  
On the other hand, TOP2 “poisons” increase the number of TOP2cc and 
generate cytotoxic lesions. Many bind to the enzyme and stabilize TOP2cc, 
preventing religation of transiently cleaved DNA strands by trapping the enzyme in 
covalent complexes on the DNA. It has also been suggested that instead of blocking 
religation, many TOP2 poisons stimulate cleavage, generating high levels of 
TOP2cc that generate DNA damage (Robinson et al., 1991). Etoposide (VP16), the 
anthracyclines doxorubicin and danorubicin, and the anthracenedione mitoxantrone 
are some of the most widely clinically used TOP2 poisons. Etoposide is an 
epipodophyllotoxin derived from podophyllotoxin (found in the American 
Mayapple). Etoposide and other TOP2 poisons are used as tools in the laboratory to 
produce TOP2 induced DSBs.  
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As an increasingly aging population affects worldwide cancer incidence, so 
does the need for selective and effective cancer treatments. Chemotherapy is one of 
the most common treatments. Exogenous agents that specifically target TOP2 can 
take advantage of the necessity for topoisomerase activity and that they induce 
transient DNA breakage (Vos et al., 2015). Etoposide, for example, is widely used 
for the treatment of various malignancies. However, TOP2 poisons such as 
etoposide also affect healthy tissues, causing undesirable side effects such as 
secondary malignancies. An example of an etoposide rooted secondary malignancy 
is translocations of mixed lineage leukemia (MLL) gene causing acute myeloid 
leukemia (t-AML), that can be linked to trapping of TOP2cc in the MLL gene 
(Lovett et al., 2001). 
Because of its expression in proliferating tissue, ideally TOP2 poisons would 
preferentially target TOP2α. Indeed, targeting of TOP2β leads to cardiotoxicity and 
highly contributes to secondary malignancies. While TOP2α and TOP2β share high 
amino acid sequence homology in the catalytic domains, it may be possible for the 
generation/identification of TOP2α-specific agents. For example, the compound 
NK314 has been observed to specifically target TOP2α (Toyoda et al., 2008).  
 
1.3. Topoisomerase 2 induced DNA damage and repair 
Topoisomerase activity has been described as a “double-edged sword,” 
referring to the essentiality of the enzymatic activity and the danger it poses to 
genomic integrity at the same time, due to the capacity to induce DSBs (Wang et al., 
1990; Liu et al., 2001; Nitiss, 2009b). As so, there is a critical balance of the level of 
cleavage complexes in order for the cell to survive, with either too few or too many 
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causing cell death. Inside the TOP2cc, the strand breaks with 4 nucleotide overhangs 
introduced by TOP2 are protected by the protein covalently bound to the 5’ DNA 
end of the break, and as such are protected. However, the DNA cleavage action of 
TOP2 does have the ability to generate DSBs and elicit the DNA damage response 
(DDR) and any collision that can incite processing can potentially generate a DSB 
(Connelly & Leach, 2004).  
For TOP2-mediated damage repair to occur, the first step involves 
recognition of the TOP2 complex as “trapped.” Recognition of a trapped covalent 
complex as damage is probably consequence of blocking replication or transcription 
(Deweese & Osheroff, 2009). Drug-TOP2-DNA complexes might remain reversible 
until processing takes place, meaning that the TOP2cc can likely revert (reseal the 
broken DNA within the cleavage complex) if recognition and repair have yet to be 
initiated (Nitiss, 2009a). Upon collision with the transcription or replication 
machinery, accumulated TOP2cc intermediates are converted into permanent DSBs. 
Figure I3. Abortive Topoisomerase 2 
activity. Upon collision with transcr ip-
tion or replication machinery, TOP2cc are 
degraded by the 26S proteasome, leaving a 
small peptide adduct still covalently linked 
to the 5’ DNA-terminus through a 
phosphotyrosyl bond. For simplicity, only 
the G-segment is shown and T-segment is 
omitted. 
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Figure I4. Resolution of abortive Topoisomerase 2 cleavage complexes. a. TOP2cc. For  simplic-
ity, only the G-segment is shown and T-segment is omitted. Simplified representation of “a” in b. 
and model for the removal of abortive TOP2cc (purple). TOP2 covalently linked to 5’ termini by 
phosphotyrosyl bond between tyrosine in the protein and phosphate of DNA is partially degraded by 
the proteasome leaving peptide of unknown size. The peptide adduct is removed by either hydrolysis 
by TDP2 (left) or nucleolytic pathways (right). The DSB is repaired by HR (bottom right) or NHEJ 
(bottom left and right). Nuclease action can be error prone, creating single or multiple nucleotide 
deletions (red box) or error free, while TDP2 processing is error free. P- phosphate, Y- tyrosine, OH- 
hydroxide. 
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Following collision, proteasome degradation of the TOP2cc by the 26S proteasome 
leaves a residual peptide adduct attached to the DNA, which must be removed or 
processed in order for DNA DSB repair to occur (Figure I3) (Mao et al., 2001). This 
is because DSBs with a chemical modification at the ends cannot be directly ligated 
(Povirk, 2012). The important proteolysis step commits to repair of the TOP2-
mediated damage, as once commenced, the enzyme probably can no longer continue 
its catalytic cycle. The major cellular protease, which is involved in this process, is 
the 26S proteasome, composed of the core 20S proteasome and 19S AAA ATPase 
regulatory complex. 
Eukaryotic cells have two main types of enzymatic activities that can repair 
TOP2-mediated DNA damage (Figure I4). The enzymatic activity of tyrosyl-DNA 
phosphodiesterase 2 (TDP2) is one way to remove the TOP2-derived peptide adduct 
(Cortes-Ledesma et al., 2009). It is hypothesized that TDP2 processes TOP2-DNA 
oligopeptides following TOP2cc degradation, although in this thesis, we will 
propose an additional mechanism that is independent of TOP2cc degradation. 
Nonetheless, TDP2 converts the blocked DNA ends into ligatable ends by cleaving 
the 5`tyrosyl phosphodiester bond. A critical question in TOP2 biology is how does 
TDP2 access the TOP2 phosphotyrosyl chemical bond, which is buried within the 
TOP2 protein shell (Wu et al., 2011), and protected from TDP2 enzymatic activity 
(Figure I5), and how this activity may be regulated. 
A second way to eliminate the residual TOP2 derived peptides in vertebrates 
is with endonucleases such as CTIP and MRE11, a component of the MRE11/
RAD50/NSB1 (MRN) complex. Gautier and colleagues used Xenopus laevis cell 
free extracts to identify MRN-CTIP-BRCA1 as an important pathway in processing 
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TOP2-DNA adducts in S-phase (Aparicio et al., 2016; Hoa et al., 2016). Paull and 
coworkers suggested an important role for CTIP and its nuclease activity for the 
resolution of TOP2-induced DSBs, a pathway possibly distinct from the MRN-CTIP
-BRCA1 pathway due to the mechanism being independent of the MRN and CTIP-
BRCA1 interaction (Makharashvili et al., 2014). Once the TOP2 block is removed, 
subsequent repair of the break can take place by one of the two main DSB repair 
pathways, further detailed below.  
 
2. Tyrosyl-DNA phosphodiesterase 2 
The laboratory of Howard Nash described the first enzyme capable of 
cleaving 3´-phosphotyrosyl bonds between proteins and DNA in Saccharomyces 
cerevisiae, and named it tyrosyl-DNA phosphodiesterase 1 (TDP1) (Pouliot et al., 
1999). Found in all eukaryotes, TDP1 is implicated in the repair of TOP1 mediated 
single strand breaks (SSB), and can also repair indirectly induced double strand 
breaks. However, mammalian TDP1 lacks the 5´phosphotyrosyl activity weakly 
detected in S. cerevisiae TDP1 and has a main 3´-TDP activity. In a genetic 
screening, Caldecott and colleagues discovered TDP2 as the first specific 5´-tyrosyl 
DNA phosphodiesterase (Cortes-Ledesma et al., 2009). TDP2 represents the only 
Figure I5. The TOP2 phosphotyrosyl chemi-
cal bond is buried within the TOP2 protein 
shell. The cellular  mechanisms that regulate 
TDP2-catalyzed phosphotyrosyl bond hydroly-
sis in poisoned TOP2cc are unknown.  
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known 5´-TDP activity in vertebrate cells, therefore the only enzyme capable of 
removing TOP2-derived structures from DSBs without having to remove adjacent 
nucleotides (Zeng et al., 2011). While TDP2 is capable of removing 3´-
phosphotyrosyl termini, it does so with at least 50-fold decreased activity compared 
to 5´-phosphotyrosyl termini (Gao et al., 2012). Nonetheless, Zeng et al. (2012) 
observed that TDP2 has a role in the repair of TOP1-mediated DNA damage in the 
absence of TDP1. However, they did not detect a role of TDP1 in the repair of 
TOP2-induced DNA damage. 
TDP2 is a member of the metal-dependent (Mg2+/Mn2+) family of phospho-
diesterases (Rodrigues-Lima et al., 2001). While not present in yeast, it is 
evolutionary conserved in metazoans. TDP2 is a pleiotropic protein with 
promiscuous interactions, not limited to DNA repair functions. The involvement of 
TDP2 in inhibition of cell growth and induction of apoptotic processes is reflected 
in the various names assigned to the protein as these functions were uncovered (Li 
et al., 2011).   
The role in tumor necrosis factor (TNF) receptor signaling (apoptosis and 
inflammatory response), warranted appointing the protein name TRAF- and TNF 
receptor-associated protein (TTRAP) (Pype et al., 2000). TDP2 has functions in the 
NFκB pathway, playing a role in TGF-β induced apoptosis. Additionally, TDP2 
inhibitory effects on ETS1, a transcription factor with roles in apoptosis, differ-
entiation, tumorigenesis, and metastasis (Li et al., 1999; Pei et al., 2003), derived the 
alternate name, ETS1-associated protein II (EAPII). 
TDP2 may also have a role in regulation of the cell cycle, as seen by Zhou et 
al. (2013). Interestingly, overexpression of TDP2 induces cell apoptosis in U2OS 
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cells (human osteosarcoma with low endogenous TDP2 expression), and cell cycle 
arrest in G2/M phase in Saos-2 cells (human osteosarcoma cells with deficient p53 
expression). TDP2 inhibitory activity on cell growth was dependent on its catalytic 
phosphodiesterase activity, as was inhibition of cyclin B1 expression in both cell 
types, a key regulator in G2/M transition, causing cell cycle arrest, which may 
account for apoptosis in the cell lines. The authors conclude that the DNA repair 
activity of TDP2 is important for its ability to modulate cell growth in osteosarcoma 
cells. Despite these additional functions, the enzymatic functions of TDP2 and its 
role in repairing TOP2 induced DSBs was sufficient enough to warrant renaming of 
the protein in 2009 to its current name. 
 
2.1. TDP2 structure 
In 2012, two TDP2 structures were simultaneously published. Aihara and 
colleagues solved the crystal structure for full-length Caenorhabditis elegans TDP2 
(cTDP2) (Shi et al., 2012) while Scott Williams’ laboratory crystallized the catalytic 
portion of Mus musculus TDP2 (mTDP2) DNA complexes (Schellenberg et al., 
2012). 
TDP2 has a modular architecture, comprised of an unstructured N-terminal 
stretch, and a small N-terminal α-helical bundle forming the ubiquitin-associated  
(UBA) like domain, which is flexibly linked to the C-terminal catalytic “EEP 
domain” (exonuclease-endonuclease-phosphatase) (Cortes-Ledesma et al., 2009; 
Figure I6. Domain organization of human TDP2. TDP2 is compr ised of a UBA domain and a 
catalytic EEP domain. UBA- Ubiquitin associated-like domain. 
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Schellenberg et al., 2012) (Figure I6). TDP2 catalytically important residues, 
residing in the EEP domain, include Glu-152, Asp-262 (Cortes-Ledesma et al., 
2009), Asn-120, and His-351 (Gao et al., 2012). The enzyme has no endo/
exonuclease activity, being highly specific for 5’Y terminus, preferring 5’single-
stranded (ss) overhangs. 
Contrary to the canonical tri-helix UBA domain structure, the cTDP2 N-
terminal domain contains four short α-helixes (Shi et al., 2012), a unique pattern 
that is conserved across species (Rao et al., 2016). It is not essential for the 5’-
tyrosyl DNA phosphodiesterase activity of TDP2 in vitro, but contains homology to 
known UBA domains, and is thus designated as a “UBA-like” domain. Aihara and 
coworkers suggest that the UBA domain is integral to the DNA repair function of 
TDP2 in vivo based on the fact that F62R mutation in the UBA-Ub interaction 
surface decreases viability in assays done with complementation of TDP2-/-/- DT40 
cells (Rao et al., 2016).  
 
2.2. TDP2 and human health 
Given its multiple roles and importance in the DNA damage response, it is 
easily conceivable that in vivo, TDP2 mutations can have serious consequences. 
Indeed, loss of TDP2 function can lead to neurological defects and TDP2 expression 
is altered in a subset of cancers (Li et al., 2011; Gómez-Herreros et al., 2014). 
Despite dramatic etoposide sensitivity, Tdp2-/- mice are phenotypically normal, 
although a large number of neuronal genes exhibit altered expression in developing 
brains and a mild loss of cerebellar interneurons was observed. Caldecott and 
colleagues identified a human homozygous TDP2 splice site-mutation causing 
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intellectual disability, epilepsy, and ataxia in affected patients. Blood and 
lymphoblastoid cell extracts from affected individuals completely lacked a 
detectable 5´TDP activity. As such, patient lymphoblastoid cells were hyper-
sensitive to etoposide and defective in repairing DSBs. 
 Additionally, TDP2 may be related to Parkinson disease (PD) pathogenesis, 
by association with DJ-1, a protein whose missense mutations are capable of 
causing early-onset recessive PD (Zucchelli et al., 2009). PD missense mutations of 
DJ-1 affect the ability of TDP2 to protect neuroblastoma cells from apoptosis 
induced by proteasome inhibition, causing cell death by JNK and P38 MAPK 
pathways.  
Furthermore, in several studies, TDP2 has been linked to viral infection. It 
was observed that TDP2 interacts with HIV-1 integrase, and facilitates lentiviral 
integration (Zhang et al., 2009). However, it has yet to be determined whether this 
function depends on TDP2 phosphodiesterase activity. Also, TDP2 was proposed to 
have a role in Hepatitis B persistence, which depends on a nuclear episome, which 
is a covalently closed circular (CCC) DNA (Koniger et al., 2014). In vitro, TDP2 
can cleave the tyrosyl-phosphodiesterase bond between the reverse transcriptase 
(RT) protein and the 5’ end of the minus strand of relaxed circular (RC) DNA, 
which must be removed in order to form CCC DNA. However, alternative work 
showed that TDP2 knockout had little effect on preventing formation of CCC-DNA 
in vivo and preventing Hepatitis B infection (Cui et al., 2015). Similarly, the 
picanovirus takes advantage of the ability of host TDP2 to remove the VPg cap 
covalently bound to RNA. The TDP2 VPg unlinkase activity removes this covalent 
linkage that stems from the replication of viral genomic RNA (Virgen-Slane et al., 
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2012). This identifies TDP2 as a potential antiviral target for treating picanovirus 
diseases, which include rhinoviruses that cause the common cold.  
 
3. DNA double strand break repair 
As aforementioned, the DNA cleavage activity of TOP2 has the ability to 
provoke the DDR, once the irreversible break with a TOP2-protein adduct 
covalently linked to DNA results from proteasomal degradation of trapped TOP2cc 
(Figure I3). The most deleterious type of genomic DNA lesions is the DSB, the type 
of strand break that can be created by TOP2 activity, and its repair its critical for 
survival and the maintenance of genome integrity (Khanna & Jackson, 2001). This 
is orchestrated by a signal transduction pathway mentioned above: the DDR. 
Activation of the DDR induces the repair of the lesions, cell cycle arrest, an 
appropriate transcriptional program and, in cases of severe damage, senescence or 
apoptosis (Ciccia & Elledge, 2010). The DNA damage signaling cascades from the 
DDR are complex, coordinated events that require the actions of various proteins 
that can be classified in different groups depending on their function. DNA damage 
sensors are proteins specifically involved in recognizing the lesion, which activate 
transducers that in turn recruit mediators, which exponentially amplify the signal. 
Finally, effectors proteins are able to carry out DNA repair, activate cell cycle 
checkpoint, remodel the chromatin or interfere with other cellular processes 
involved (Polo & Jackson, 2011). 
In the particular case of DSBs, the KU70–KU80 heterodimer and the MRN 
complex are earliest factors to bind to DSBs (Lisby 2004). After DSB recognition, 
three different phosphatidylinositol 3-kinase-related kinases (PIKKs) can be 
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recruited to sites of damage: DNA-PKcs (DNA-dependent protein kinase catalytic 
subunit), ATM (Ataxia Telangiestasia-Mutated) and ATR (ATM- and Rad3-
Related); serving as a transducers of the signal by phosphorylating numerous 
proteins (Marechal & Zou, 2013). With the help of mediator proteins, ATM and 
ATR can activate the effector kinases CHK1 and CHK2, which then spread the 
signal throughout the nucleus to trigger cell cycle arrest. This prevents adverse 
consequences of DNA lesions and their transmission to daughter cells (Polo & 
Jackson, 2011). Eventually, if the DNA damage cannot be repaired, DDR 
participates in activating apoptosis, which is essential to remove potentially 
dangerous cells from the organism (Roos & Kaina, 2013). 
One significant feature of DDR proteins is their local accumulation at 
damage sites (Polo & Jackson, 2011). Taking the advantage of this characteristic, it 
is possible to detect discrete foci by immunofluorescence techniques (Costes et al., 
2010). Through this method, DSB induction and disappearance have been analyzed 
for last 20 years (Rogakou et al., 1999). It is worth noting that one of the earliest 
events in DSB signaling is the phosphorylation in Serine139 of histone variant 
H2AX (known as γH2AX), which can be carried out redundantly by ATM, ATR 
and DNA-PKcs. The number of nuclear γH2AX foci corresponds well with the 
number of DSBs, and when counted in immunofluorescence staining, serves as a 
good tool to estimate DSBs. 
The two main pathways in cells for repairing DSBs are nonhomologous end-
joining (NHEJ) and homologous recombination (HR). HR takes advantage of 
homologous DNA sequences as a template to perform error free DSB repair, 
therefore is limited to the S and G2 phases of the cell cycle due to the requirement 
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for the sister chromatid as a template (Rothkamm et al., 2003). NHEJ, the main 
DSB repair pathway in mammalian cells, is a faster repair process, and directly 
ligates broken DNA ends throughout most of the cell cycle (Figure I7). 
NHEJ plays a dominant role in repairing etoposide-induced DSBs, which is 
the main pathway that follows TOP2-residual peptide removal by TDP2 (Gómez-
Herreros et al., 2013). In the mammalian NHEJ pathway, the DSB is first 
recognized by the dimeric proteins KU70-KU80 (Ku), which binds DNA ends 
specifically and serves as a loading protein to which other NHEJ proteins can be 
Figure I7. DNA DSB repair by non-
homologous end joining. KU recognizes 
the DSB and binds the DNA ends, followed 
by DNA-PKcs recruitment to form the DNA-
PK complex. DNA-PKcs is phosphorylated, 
and disassembled from the DNA. Accessory 
proteins XRCC4 and XLF form helical fila-
ments bridging DNA ends, while LIG4 per-
forms ligation of the broken DNA ends.  
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recruited. Ku translocates inwards allowing DNA-PKcs to bind DNA ends, together 
forming the DNA-PK complex, which bridges and stabilizes the ends (Meek et al., 
2008). DNA-PKcs protein kinase activity is stimulated, and it is 
autophosphorylated, which prompts a conformational change that promotes its 
release from DNA ends (Lees-Miller & Meek, 2003). Accessibility of the DSB to 
other repair factors is regulated by this assembly and disassembly, and DNA-PKcs 
autophosphorylation seems to be required for the NHEJ pathway to proceed. DNA 
ligase IV (LIG4) is recruited and performs ligation of broken DNA ends. This is 
helped by cofactor X-Ray Cross Complementing Protein 4 (XRCC4), XRCC4-Like 
Factor (XLF), Aprataxin-and-PNK-Like Factor (APLF), and PAralog of XRCC4 
and XLF (PAXX) (Mari et al., 2006; Uematsu et al., 2007; Ochi et al., 2015), which 
are accessory proteins that directly or indirectly favor end-bridging and ligation 
(Roy et al., 2015; Liu et al., 2017). 
On the other hand, the mammalian MRE11/RAD50/NBS1 complex (MRN 
complex) initiates DSB repair by HR, recognizing and stabilizing broken 
chromosome ends (Lisby et al., 2004; Paull & Deshpande, 2014). CTIP promotes 
the process of extensive end resection, which is performed by MRE11 nuclease 
activity, committing the repair pathway to HR and inhibiting NHEJ. Importantly, 
while DSB induction strongly activates ATM and DNA-PKcs, ATR is recruited to 
DSBs specifically when DNA is resected (Shiotani & Zou, 2009b). The nuclease 
action creates 3’-single stranded ends, which are rapidly coated with Replication 
Protein A (RPA), protecting DNA ends (Alani et al., 1992; Mimitou & Symington, 
2010). The MRN complex is important for controlling resection, and also has a role 
in recruiting and activating the kinase ATM.  RPA is then replaced by the 
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recombinase RAD51 that forms a filament that aids in the search for the 
homologous DNA sequence and strand invasion. The invading strand serves as a 
template for DNA synthesis and allows the restoration of the disrupted genetic 
information. 
 
4.  Sumoylation 
The human genome has a set of approximately 25,000 genes, which 
amazingly leads to a human proteome with over one million proteins. This variation 
comes at the transcriptional and mRNA level, from alternative promoters, 
differential transcription termination, and alternative mRNA splicing (Auoubi, 
1996). Post-translational protein modifications (PTMs) are a clever way of further 
augmenting that complexity and diversity by adding small moieties, or even small 
proteins, to specific amino acid residues (Human Genome Sequencing Consortium, 
2004).  PTMs can affect activity, localization, and interaction with other molecules. 
They offer a quick and reversible way of changing substrate function without de 
novo protein synthesis (Ulrich, 2012b). The most common mechanism of action is 
the creation of interaction surfaces followed by recognition by downstream effector 
proteins through dedicated binding domains (Ulrich, 2012a). The updated UniProt 
database is a testament to the remarkable number of post-translational modifications 
that have been identified (The UniProt Consortium http://www.uniprot.org/docs/
ptmlist).  
A few well studied post-translational modifications include phosphorylation, 
acetylation, methylation, glycosylation, ubiquitination, and sumoylation. Different 
PTMs can even work together and influence each other (Ulrich, 2005). Covalent 
tagging of a protein by a second protein was first discovered with ubiquitin, which 
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links to a receptor lysine residue in a step-by-step conjugation cascade. Poly-
ubiquitination occurs when further ubiquitin molecules are conjugated to each other 
by isopeptide bonds between the ubiquitin molecules and the lysine of the bound 
ubiquitin. Ubiquitination controls a myriad of processes, and as such, there are 
numerous downstream responses (Dikic et al., 2009). Histone ubiquitination, for 
example, is able to alter chromatin structure (Desterro et al., 1999) and poly-
ubiquitination commonly signals for proteasomal degradation. 
Sumoylation is another type of post-translational modification that involves 
covalent conjugation of a small protein, SUMO (Small Ubiquitin-like MOdifier) to 
a target lysine of a specific protein, in a manner similar to ubiquitin. While SUMO 
and ubiquitin share only 18% identity, the three dimensional structure is similar 
(Mahajan et al., 1997). Yeast and invertebrates have only one isoform (SMT3 in S. 
cerevisiae). The three main SUMO isoforms in mammalian cells are SUMO1, 2 and 
3. SUMO1 shares about 48% sequence identity with SUMO2 and 46% identity with 
SUMO3. SUMO2 and 3 share 96% identity (Saitoh & Hinchey, 2000). SUMO2 and 
SUMO3 will be referred to as SUMO2/3 in this thesis when they are 
indistinguishable. A fourth isoform, SUMO4, is expressed in mammals, although it 
is not expressed in most tissues. Nonetheless, SUMO4 mRNA is expressed in 
kidney cells. On the other hand, SUMO modification can occur on the same lysine 
as ubiquitination, thereby inhibiting poly-ubiquitin mediated proteasomal 
degradation (Desterro et al., 1998).  
SUMO1 was identified simultaneously by several groups (Okura et al., 
1996, Shen et al, 1996; Boddy et al., 1996; Mahajan et al., 1997; Matunis et al., 
1996). In a screening performed by Okara and colleagues (Okura et al., 1996), 
 26 
INTRODUCTION 
SUMO was identified and named Sentrin, with TNF receptor 1 interactions 
detected. Chen and coworkers (Shen et al., 1996) also identified SUMO as a small 
protein with homology to ubiquitin that associates to human RAD51 and RAD52 
DNA DSB repair proteins, noting high expression in many tissues, especially testis. 
They named it UBL1 for Ubiquitin-Like 1. At the same time, utilizing a human 
cDNA library, Freemont and colleagues (Boddy et al., 1996) screened for PML 
(ProMyelocytic Leukemia protein) interacting clones and identified SUMO1 
(referred to as PIC1). This represented the first nuclear body (NB)-associated 
protein identified to interact with PML (PMB NBs are further detailed below).  
One of the most important SUMO1 targets in the cell is RANGAP1, the 
GTPase-activating protein for RAN, which is linked to nuclear import. Melchior 
and colleagues discovered that a small ubiquitin-related peptide, which they named 
SUMO1, was required for RANGAP1 localization to the nuclear pore complex 
(NPC) (Mahajan et al., 1997). Simultaneously, Blobel and colleagues also identified 
SUMO1 as the covalent modification of RANGAP1, and designated it as GMP1 
(Gap modifying protein 1) (Matunis et al., 1996).  
 
 
4.1. SUMO conjugation 
There are important distinctions between the SUMO1 and SUMO2/3 
conjugation pathways. In mammalian cells, there is relatively little free SUMO1, 
with 90% being conjugated (Kamitani et al., 1997). In the cell, there is a larger pool 
of free SUMO2/3 than SUMO1. Protein damaging stimuli induces SUMO2/3 
conjugation to high molecular weight proteins, indicating a role in cellular response 
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to environmental stress (Saitoh & Hinchey, 2000). SUMO2/3 has a N-terminal Ψ-K-
X-E substrate consensus motif and can form polymeric chains on protein substrates. 
SUMO1 does not form chains, but can cap SUMO2/3 chains. The majority of 
SUMO modified proteins are in the nucleus, but also cytosolic targets have been 
identified. 
60% of covalent SUMO modification occurs in sites that follow this 
modification consensus sequence, Ψ-K-X-E (Qi et al., 2014). The first amino acid, 
Ψ, is a large hydrophobic amino acid, such as A, I, L, M, P, F, V or W. The second 
amino acid is the lysine that receives the covalent SUMO conjugation, and the third, 
represented by X, can be any amino acid residue. The fourth amino acid is glutamic 
acid, which has a negative charged side chain. 
Figure I8. SUMO conjugation cycle. Inactive SUMO precursor  is processed by a SENP to ex-
pose the C-terminal di-glycine motif during the maturation process. Mature SUMO (SUMO-GG rep-
resented as SUMO) is then activated by SUMO activating enzyme (E1). Next, it is transferred by 
transesterification to the E2, which is UBC9. Conjugation to the target lysine follows, which can be 
facilitated by an E3 SUMO ligase. Deconjugation from substrates is carried out by specific SENPs 
(SUMO-specific proteases). 
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SUMO conjugation is similar to that of Ubiquitin, with own specialized en-
zymes that help form the isopeptide bond between carboxyl terminus of SUMO and 
the designated lysine side chain of target protein (Figure I8). The C-terminal 
diglycine residue of SUMO is essential for conjugation to other proteins (Kamitani 
et al., 1997). SUMO is translated as a precursor, and the four amino acids of the C-
terminus (His-Ser-Thr-Val in SUMO1) following the Gly-Gly residues must be 
removed post-translationally prior to conjugation. SUMO deconjugation is carried 
out by SUMO isopeptidases, SUMO-specific proteases/Sentrin proteases (SENPS). 
This 6-member family of cysteine proteases is responsible for maturation, 
deconjugation, and depolymerization of SUMOs (Nayak & Muller, 2014) and 
allows for the reserve of free SUMO. 
The E1 SUMO activating enzyme, a heterodimeric protein of SAE1 and 
SAE2 in humans (SUMO Activating Enzyme) (Desterro et al., 1999), catalyzes 
ATP-dependent formation of thioester linkage between SUMO and SAE2. UBC9, 
the E2 conjugating enzyme for SUMO, transfers thioester-linked SUMO to itself in 
a transesterification process (Johnson et al., 1997). The last step of SUMO 
conjugation involves the formation of an isopeptide bond between SUMO and the 
target substrate, facilitated by the action of UBC9 and E3 protein ligases.  
SUMO1 conjugation in vitro does not require E3 protein ligase activity 
equivalent to E3 ubiquitin protein ligase in ubiquitin conjugation (Desterro et al., 
1999). Additionally, the E1 and E2 enzymes do not discriminate among SUMO 
isoforms 1-3 (Tatham et al., 2003). The E3 enzyme can act to add specificity to 
targets. Some examples of known SUMO E3 ligases are RanBP2, Polycomb Protein 
PC2 (CBX4) and the PIAS family. 
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Additionally, the sumoylation pathway has a noteworthy role in the DDR, 
with SUMO being necessary to maintain genome stability. DNA damage induces a 
sumoylation wave of various proteins at multiple sites, mediated by the E3 SUMO-
ligases PIAS1 and PIAS4, in order to foster protein-protein interactions and increase 
repair rate. As a matter of fact, SUMO, UBC9, PIAS1 and PIAS 4, and two of their 
substrates, BRCA1 and 53BP1, are relocated to γH2AX foci upon DNA damage. 
Because of the relevance of sumoylation in the cell, there is a continued 
search for additional proteins that can serve as components of the sumoylation 
machinery. Recently, the novel protein Zinc Finger Protein 451 (ZNF451) was 
identified as a possible novel class of SUMO E3 ligases. 
 
4.2. SUMO-interacting motifs 
When covalent SUMO modification of a protein serves to provide a binding 
site for other proteins, this is likely due to a SUMO interacting motif (SIM), also 
known as SUMO binding amino acid sequence motif (SBM), on interacting 
proteins, creating sumoylation-dependent protein-protein interactions (Song et al., 
2004). SIMs have been identified in numerous types of proteins including SUMO 
ligases, transcription factors, and transcription repressors. Not all predicted SIMs 
are functionally relevant, as a given SIM may not be functionally exposed in a 
protein structure. Additionally, there is no one “universal SIM.” 
With screening using human cDNA, a general SIM motif consisting of a 
hydrophobic core sequence flanked by an acidic region has been described, h-h-X-S
-X-S/T-a-a-a (see Table 2) (Minty et al., 2000). The motif was found in PIASx and 
is conserved in the PIAS and PKY gene families. The SIM consists of a serine 
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doublet separated by an amino acid (S-X-S/T), with a possible substitution of the 
second serine for threonine. The N-terminal side is composed of hydrophobic amino 
acids (h), while the C-terminus has acidic amino acids (a) such as aspartic acid (D) 
or glutamic acid (E). 
In 2004, Song and colleagues described V/I-X-V/I-V/I as a SIM able to bind 
to the main SUMO paralogues in mammalian cells (SUMO1, SUMO2, and SUMO3 
were tested) albeit with different affinities. Valine and isoleucine are exchangeable 
in the SIM sequence, as both are similar and have branched aliphatic side chains. 
The publication of this SIM refuted the dominant role of the serine residues as 
published by Minty et al. (2000). The V/I-X-V/I-V/I SIM is important, for example, 
for the sumoylation-mediated protein-protein interaction between RANGAP1 and 
RANBP2 (Song et al., 2004). The hydrophobic core, often adjacent to a negatively 
charged acidic cluster of amino acids, is an essential component of SUMO-
interacting motifs.  
Hannich and coworkers (2005) derived a yeast SIM from  data of clones 
(FIR1, RIS1, SAP1, and NIS1) that bound a non-conjugatable form of yeast SUMO 
(SMT3): K-X3-5-I/V-I/L-I/L-X3-D/E/Q/N-D/E-D/E. Similar to the SIM described by 
Minty and colleagues (2000), there is both an N-terminal hydrophobic cluster and C
-terminal acidic cluster.  
Hecker et al. (2006) highlight the importance of hydrophobic residues, 
analyzing previously published SIMS and, in combination with their results, they 
proposed a universal SIM with hydrophobic core sequence with stretches of three or 
four hydrophobic isoleucine, leucine, or valine residues [V/I/L] plus one acidic/
polar residue at position 2 or 3. Surrounding this core domain is a disordered 
 31 
INTRODUCTION 
sequence of acidic amino acid residues with a net negative charge. The majority of 
SIMs contained serines or threonines, separating the acidic and hydrophobic parts of 
the SIM, which can serve as possible phosphorylation sites (Hecker et al., 2006). In 
fact, the phosphorylation of serine in the SIM of PIASxα may contribute to the 
spatial orientation of binding to sumoylated targets. 
Ouyang and colleagues identified a non-consensus SIM required for 
SUMO2 specific binding, I/V/L-D/E-I/V/L-D/E-I/V/L (Ouyang et al., 2009). Their 
results indicated that interaction between the SIM of CoREST1 (part of the LSD1/
CoREST1/HDAC co-repressor complex) and SUMO2 mediates changes in 
chromatin structure and transcription, relevant for cell type-specific gene 
expression. Additionally, Vogt and Hofmann published three SIMS in 2012 (Vogt 
& Hofmann, 2012).  
Interestingly, Hecker and colleagues identified a potential SIM in human 
TDP2, 280IVDV283, an inversion of the predicted SIM V/I-X-V/I-V/I (Hecker et al., 
2006). Song and coworkers showed that both parallel and antiparallel binding to 
SUMO could occur, indicating the possibility of these amino acids serving as a 
SUMO-binding domain (Song et al., 2005). The potential SIM of TDP2 lacked the 
characteristic acidic track (SIM with surrounding sequence: RCGGLPNNIVDV-
WEFLGKPKH), which influences general SIM binding to SUMO1 but not SUMO2 
(Hecker et al., 2006). Mutating the four amino acids of TDP2 280IVDV283 to 
alanines, Hecker and colleagues observed that binding to SUMO isoforms is 
abolished. To test the contribution of negatively charged residues in isoform specific 
binding, Leucine286, Glycine287, and Lysine288 were mutated to glutamine, aspartic 
acid, and glutamine. SUMO1 binding was increased, while SUMO2 binding 
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decreased. The N-terminal domain of TDP2 UBA-like domain is specific for 
ubiquitin binding, and does not bind SUMO (Rao et al., 2016). 
 
4.3. ZNF451 is a novel SUMO E3 ligase 
ZNF451 is a 121 kDa multi-zinc finger SUMO E3 ligase specific to 
SUMO2/3 that acts as a transcriptional coregulator through its interactions with both 
PML bodies and the SUMO machinery (Cappadocia et al., 2015; Eisenhardt et al., 
2015). Of the three alternatively spliced isoforms of the protein, isoform 1 (121 kDa 
protein) is the most expressed (Figure I9). Isoform 1 and 2 are almost identical, with 
isoform 3 only sharing the catalytic N terminal, pointing towards different substrate 
specificity and/or function. 
ZNF451 integrates the function of SIMs and E3 activity to constitute a novel 
way of performing sumoylation. ZNF451 itself is autosumoylated in an atypical 
manner, in that the sumoylation at several non-consensus sites actually depends on a 
SIM within the protein (Eisenhardt et al., 2015). It is interesting that the covalent 
SUMO binding depends on a non-covalent SUMO interaction. Two N-terminal 
SIMs with an intervening proline-leucine-arginine-proline (PLRP) motif are 
responsible for the SUMO E3 ligase activity (Cappadocia et al., 2015). ZNF451 has 
the ability to elongate SUMO2/3 chains, an activity that has been proposed as an 
Figure I9. Domain organization of ZNF451. Colored boxes represent domains/motifs of 
ZNF451. The N-terminus of ZNF451 contains two SIMs with an intervening PLRP domain. ZNF451 
also contains twelve C2H2 type zinc fingers, and a C-terminal UIM. SIM-Sumo Interacting Motif 
(red); PLRP- Proline-Leucine-Arginine-Proline motif (purple); UIM- ubiquitin interacting motif 
(blue); C2H2 type zinc fingers (green). This figure is based on Cappadocia et al., 2015. 
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“E4 elongase activity.” The zinc finger region of the protein mediates substrate 
specificity while SUMO modifications are important for nuclear localization of 
ZNF451 (Karvonen et al., 2008). ZNF451 interacts weakly with androgen receptor 
(AR) in a SUMO1 enhanced manner.  
Additionally, ZNF451 partially colocalizes to PML NBs, and while PML is a 
SUMO substrate of ZNF451, ZNF451 also regulates PML stability (Koidl et al., 
2016). PML NBs are a functional promiscuous proteinaceous sub-nuclear 
compartments that are organized by the PML protein, and are implicated in diverse 
cell functions, such as stress response, DNA repair, apoptosis, and anti-viral 
immunity (Bernardi & Pandolfi, 2007; Sahin et al., 2014b). PML nuclear bodies 
may play an important role in integrating the sumoylation and ubiquitination 
pathways with SUMO1 and ubiquitin co-localizing in PML bodies upon inhibition 
of the proteasome (Bailey & O’Hare, 2005). Interestingly, like ZNF451, TDP2 is 
also a PML NB component (Xu et al., 2008). 
 
4.4. Sumoylation of Topoisomerase 2 
SUMO modification of topoisomerases was first discovered with TOP1, 
before being discovered in TOP2. Trapped TOP1 activates the ubiquitin/26S 
proteasome and results in its degradation (Mao et al., 2000b). Given these results, 
Liu and colleagues investigated if TOP2-induced damage induces sumoylation and/
or degradation of TOP2. TOP2 damage does, in fact, induce sumoylation. For 
example, both the TOP2 poison teniposide (VM-26) and bisdioxopiperazine 
inhibitor ICRF-193 cause rapid SUMO1 modification of TOP2α and TOP2β in 
HeLa cells (Mao et al., 2000a). Sumoylation can be an early signal for TOP2β 
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selective degradation by the nuclear proteasome following exposure to ICRF-193. 
When SUMO and UBC9 are conditionally knocked out, ICRF-193 induced 
degradation of TOP2β doesn’t occur. ICRF-193 catalytic inhibitor traps TOP2 in 
the closed clamp conformation, not inducing TOP2-mediated DNA damage, 
which suggests that the conformational change of TOP2 may be the signal that 
triggers SUMO1 conjugation. The structure of TOP2 protein clamp on DNA 
induced by the drug can also be an obstacle for processes, therefore one could 
expect accelerated degradation (Isik et al., 2003). The pathway for degradation of 
TOP2cc was further elucidated, when Ban and colleagues observed that TOP2βccs 
arrest RNAPII transcription elongation and induce proteasomal degradation of 
TOP2β by a ubiquitin-free pathway that involves 20S proteasome and 19S AAA 
ATPases, components of the 26S proteasome (Ban et al., 2013). 
In addition to the response to damage, sumoylation of TOP2 plays an 
important role in mitosis. TOP2α is sumoylated in two distinct regions, at several 
sites in the C-terminal domain (CTD) and at lysine 660 (in Xenopus laevis) in the 
catalytic core of the enzyme where cleavage and relegation of DNA occur (Ryu et 
al., 2010). As previously mentioned, in order for correct chromosome segregation 
to occur, sister chromatid cohesion must resolve properly, with TOP2α 
decatenating centromeric DNA (Lee & Bachant, 2009). Although TOP2α can be 
found bound throughout the chromosome, the majority of the sumoylated form is 
found clustered at the mitotic centromere in early mitosis (Ryu et al., 2010). It has 
been suggested that this sumoylation is important for the localization of the 
histone H3 kinase Haspin and histone H3 phosphorylation at the centromere, 
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which are important for the recruitment of other mitotic factors (Yoshida et al., 
2016a). 
There is evidence that different E3 SUMO ligases are involved in TOP2 
sumoylation. In vertebrates, Dasso and colleagues used X. laevis egg extracts to 
demonstrate that PIASy is responsible for SUMO2/3 modification of TOP2α, 
important for the remodeling of TOP2 on mitotic chromosomes at the metaphase-
anaphase transition (Azuma et al., 2003; Azuma et al., 2005). However, a different 
SUMO ligase has also been implicated in TOP2α sumoylation through SUMO1 
modifications. The RANBP2 SUMO E3 ligase domain binds to TOP2α in mitosis 
and regulates its sumoylation and localization to inner centromeres, to mediate 
sister-chromatid segregation. (Joseph et al., 2004; Dawlaty et al., 2008).  
While TOP2 sumoylation has an important role in both the DDR and 
mitosis, until now it has remained unknown whether or not TOP2 is sumoylated in 
the context of the cleavage complex. Additionally, if TOP2cc are SUMO modified, 
the E3 SUMO ligase responsible has not been identified and may or may not be one 
of the known TOP2 E3 SUMO ligases mentioned above.  
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Table I1. Human Topoisomerases. There are six topoisomerases present in Homo sapiens, in-
cluding type IA, type IB, and type IIA. Adapted from Pommier et al., 2016.  
Table I2.  Selected identified SIMs. Hydrophobic and acidic amino acids are impor tant in pub-
lished general and specific SIMs. 
Select SIMs Reference 
h-h-X-S-X-S/T-a-a-a  Minty et al., 2000 
V/I-X-V/I-V/I Song et al., 2004 
K-X3-5-I/V-I/L-I/L-X3-D/E/Q/N-D/E-D/E Hannich et al., 2005 
V/I/L/M/F/W/A-V/I/L/M/F/W/A-X-S-X-S/T-D/E-D/E-D/E Hecker et al., 2006 
I/V/L-D/E-I/V/L-D/E-I/V/L  Ouyang et al., 2009 
P/I/L/V/M-I/L/V/M-X-I/L/V/M-[D/S/E/>]3 Vogt et al., 2012 
P/I/L/V/M-I/L/V/M-D/L/T Vogt et al., 2012 
[D/S/E]3-I/L/V/M-X-[I/L/V/M/F]2 Vogt et al., 2012 
  Classification 
DNA 
end Cofactors 
Supercoiled 
substrates Other substrates 
TOP1 Type IB 3’  None +, -  
TOP1mt Type IB 3’  None +, -  
TOP2α Type IIA 5’  Mg2+ and ATP +, - knots, catenanes 
TOP2β Type IIA 5’  Mg2+ and ATP +, - knots, catenanes 
TOP3α Type IA 5’  Mg2+  - 
Hemicatenanes, Double 
Holiday Junctions, D 
TOP3β Type IA 5’  Mg2+  - RNA knots, R loops 
5. INTRODUCTION TABLES 
II. OBJECTIVES 
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II. Objectives 
Because TOP2 is sumoylated in several physiological processes and in re-
sponse to etoposide, and TDP2 has been reported to interact with SUMO through a 
published SIM, we aimed to uncover novel functions of TDP2 in the resolution of 
TOP2cc, the possible role of SUMO, and novel factors involved in the process, there-
fore updating the current model for the removal of TOP2cc. Hence, the objectives of 
this thesis are as follows: 
1. Characterization of non-covalent TDP2-SUMO interactions. 
1.1. Verify SUMO isoform specific interactions with TDP2. 
1.2. Define and characterize the SIM of TDP2. 
1.3. Determine the physiological relevance of TDP2 interaction with SUMO.  
2. Role of TOP2 sumoylation and effect of TDP2. 
2.1. Address TOP2 sumoylation in the context of the cleavage complex. 
2.2. Determine a possible role of TDP2 on sumoylated TOP2cc. 
III. RESULTS 
RESULTS 
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1. TDP2 is a SUMO binding protein 
 TDP2 is a pleiotropic protein involved in various cellular processes. Upon 
the discovery of its unique 5’phosphodiesterase activity (Cortes-Ledesma et al., 
2009), and in order to further characterize the protein, Felipe Cortés-Ledesma and 
Maria C. Zuma (in the laboratory of Keith Caldecott) performed a yeast two-hybrid 
(Y2H) screening utilizing TDP2 as bait (TDP2 cDNA cloned into the pGBKT7 vec-
tor) with a pACT human cDNA library.  
To perform a Y2H, a gene of interest is cloned into an expression vector to 
express the protein (designated as the ‘bait’) as a fusion to the DNA binding domain 
(BD) of a transcription factor (TF). In this case, TDP2 was used as a C-terminal bait 
protein fused to amino acids 1-147 of the GAL4 DNA BD.  A second hybrid is con-
Figure 1. Yeast two-hybrid principle and potential TDP2-interacting factors. a. Yeast two-
hybrid principle. A fusion ‘hybrid’ is constructed between a protein of interest, the ‘bait’, and the 
DNA Bind-ing Domain (DNA BD) of the transcription factor (TF). A second hybrid is constructed 
between the ‘prey’ protein and the Activation Domain (AD) of the TF. Interaction between the bait 
and the prey brings the DNA BD and AD in close proximity and a functional TF is reconstituted 
upstream of the reporter gene. From www.hybrigenics-services.com. b. List of potential TDP2-
interacting factors identified in a yeast two-hybrid screening against a cDNA library. Courtesy of 
Maria C. Zuma, Felipe Cortés-Ledesma, and Keith Caldecott. 
Y2H Hits 
Sumo 1 
Sumo 2 
UBC2I 
PIAS1 
PIAS3 
Ubiquitin B 
RYBP 
BTBD6 
RIOK1 
PCBP1 
SCRN1 
TPT1 
RPL13 
C5orf15 
PRMT1 
RPS3A 
PHB2 
HNRNPA2B1 
PABPC1 
PCNA 
CYBASC3 
a. b. 
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structed between a prey protein and the activation domain (AD) of the GAL4 TF. 
As depicted in Figure 1a, interaction between the bait and prey indirectly connects 
the AD and BD of the transcription factor, the AD is brought into proximity of the 
transcription start site (TSS), allowing transcription of the reporter gene HIS3, per-
mitting growth in histidine-lacking media. Since HIS3 has leaky expression in many 
yeast strains, including Y190, a competitive inhibitor of the HIS3 gene product, 3-
Amino-1,2,4-Triazol (3AT), was added to -His plates at a concentration previously 
determined by titer to remove background. pGBKT7 contains the TRP1 nutritional 
marker while the pACT vector contains the LEU2 marker, allowing yeast auxo-
trophs to grow on the corresponding limiting synthetic media.  
 Surprisingly, of 62 isolated candidates of the Y2H screening, 14 corre-
sponded to SUMO1, 12 to SUMO2, and 10 to UBC2I, homolog of the SUMO con-
jugating enzyme UBC9 (Figure 1b). Additional members of the SUMO conjugation 
machinery were identified such as the E3 SUMO ligases PIAS1 and PIAS3. Ubiqui-
tin was also detected in the screening. The interactions detected with SUMO and the 
sumoylation machinery through the Y2H opened the possibility of TDP2 having a 
physiologically relevant interaction with SUMO.  
 TDP2 interactions with SUMO were confirmed with directed Y2H studies 
and the SUMO isoform specificity was tested, checking which (if any) interacts 
more strongly with TDP2. pGBKT7-TDP2, the vector utilized for the Y2H screen-
ing, was used. SUMO1 and SUMO2 were cloned into the pACT vector to express 
the corresponding prey proteins fused C-terminally to the GAL4 activation domain 
(AD). After transformation of these vectors into the Y190 strain (see methods table 
1 for genotype) and selection on –Leu –Tryp plates, individual yeast colonies con-
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taining both plasmids were selected and 5X drop dilutions were performed on -Leu -
Tryp plates to represent growth, serving as a loading control (left panel of Figure 2). 
Interaction was represented in the right panel, by growth on -Leu -Tryp -His plates.  
Figure 2. Yeast two-hybrid interactions of SUMO with TDP2. Yeast two-hybrid interactions of 
SUMO with TDP2. 5X drop dilutions plated on (-Leu -Tryp) plates (left) or (-Leu -Tryp -His) 
plates with the addition of 3AT (right). a. TDP2 bait in combination with prey of empty vector (EV) 
control  pACT (BD alone), SUMO1, or SUMO2. b. TDP2 bait in combination with prey of control 
pGBKT7 (AD alone), non-conjugatable SUMO 1 (SUMO1-NC), or non-conjugatable SUMO2 
(SUMO2-NC). c. pGBKT7(AD alone) with EV, SUMO1, or SUMO2.  
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Growth on -Leu -Tryp -His plates was observed for yeast cotransformed 
with pGBKT7-TDP2 and both pACT-SUMO1 and pACT-SUMO2, indicative of 
interaction (right panel of Figure 2). More growth was observed for pGBKT7-TDP2 
+ SUMO2 than for pGBKT7-TDP2 + SUMO1, indicating a stronger interaction 
with SUMO2 as compared to SUMO1 (Figure 2a). As expected, there was no 
growth of yeast transformed with pGBKT7-TDP2 and the empty pACT vector con-
taining only the AD on -Leu -Tryp -His plates, indicating that the SUMO interac-
tions are specific. Additionally, the empty pGBKT7 vector containing only the BD 
did not interact with the AD (pACT) nor with SUMO (Figure 2c). 
The TDP2 and SUMO interaction could be representative of either a non-
covalent SUMO interaction through a TDP2 SIM or covalent conjugation of SUMO 
to the TDP2 protein. In order to check this, we made use of non-conjugatable 
SUMO1 and SUMO2 lacking the C-terminal diglycine motif important for covalent 
SUMO conjugation, a gift from Mario García (CABIMER), in the pLexA vector 
containing the LexA DNA binding domain and the TRP1 nutritional marker. TDP2 
was cloned into the pACT vector. TDP2 interaction did not decrease for either iso-
form when the non-conjugatable forms of SUMO were used, indicating that cova-
lent sumoylation was not necessary for the observed interaction (Figure 2b).  
Our results were consistent with the observations of Dikic and colleagues 
(Hecker et al., 2006), who used non-conjugatable SUMO1 or SUMO2 as bait to per-
form a large scale Y2H screening with human cDNA libraries to identify SUMO 
interacting partners. They identified several proteins, one of which was TTRAP 
(TDP2), with a stronger interaction detected with SUMO2 as compared to SUMO1 
in both yeast and cells. 
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Using the program GPS-SUMO 1.0 (Qi et al., 2014) with a medium thresh-
old, there was a predicted SUMO-interacting motif (SIM) in human TDP2 at 
280IVDV283 (isoleucine, valine, aspartic acid, isoleucine) with a score of 59.475 
(Figure 3b). Only the aspartic acid residue is conserved in the mouse protein (Figure 
3a), although it is surrounded by different hydrophobic residues, 290VFDA293. Heck-
er et al. (2006) also identified the same SIM in human TDP2 as the prediction soft-
ware.  
280IVDV283 is an inversion of the predicted SIM V/I-X-V/I-V/I (Hecker et 
al., 2006). Song and colleagues showed that both parallel and antiparallel binding to 
Figure 3. Alignment of mouse and human TDP2 with predicted SIM. a. TDP2 amino acid se-
quence alignment of Homo sapiens (human) and Mus musculus (mouse). Amino acids conserved 
between the two species are marked with an asterisk, and amino acids with high homology are 
marked with two dots, and with less homology marked with one dot. Predicted SIM and homologous 
sequence is marked in blue. b. SUMO prediction: Predicted Sumo-Interacting Motifs (SIMs) in Ho-
mo sapiens TDP2. 
ID Position Peptide Score Cutoff Type 
hTDP2 280 - 284 CGGLPNN IVDVW EFLGKPK 59.475 55.31 SUMO Interaction 
a. 
b. 
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SUMO could occur, indicating the possibility of these amino acids serving as a SU-
MO-binding domain (Song et al., 2005). The potential SIM of TDP2 lacked the 
characteristic acidic track (SIM with surrounding sequence: GLPNNIVDV-
WEFLG), which influences general SIM binding to SUMO1 but not SUMO2 
(Hecker et al., 2006). Mutating the four amino acids of TDP2 280IVDV283 to ala-
nines, Hecker and colleagues observed that binding of the TDP2-SIM mutant to SU-
MO isoforms is abolished. We then wanted to perform complementation experi-
ments in mammalian cells to see the physiological relevance of the TDP2-SUMO 
Figure 4. Yeast two-hybrid interactions of TDP2 with SUMO are abolished by SIM mutation. 
Yeast two-hybrid interactions with TDP2-SIM. a. 5X drop dilutions (left) plated on (-Leu -Tryp) and 
(right) (-Leu -Tryp -His). TDP2 bait in combination with prey of control (EV), SUMO1, or SUMO2. 
b. Immunoblot of  yeast transfor med with transfected with pGBKT7 empty vector  (EV) con-
taining GAD, TDP2 fused to GAD, or TDP2-SIM fused to GAD with GAD antibody. c. Immunoblot 
of HEK 293T cells transfected with empty pcDNA3.1 vector (EV), TDP2, or TDP2-SIM with TDP2 
antibody. Arrows indicate the expected size of GAD-TDP2 or TDP2. 
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interaction, so we complemented Tdp2-/- MEFs, which have several known DSB 
repair phenotypes, with wild-type TDP2 and TDP2 that no longer interacted with 
SUMO. In order to do this, similar to the construct used by the Dikic laboratory 
(Hecker et al., 2006), we recreated the construct TDP2-SIM and cloned it into the 
pGBKT7 vector. With Y2H, we confirmed that TDP2-SIM loses the ability to inter-
act with both SUMO1 and SUMO2 (Figure 4a). We checked expression in yeast, 
and confirmed that the transformed yeast properly express TDP2-SIM, even more so 
than wild-type TDP2 (Figure 4b). However, when we attempted to express TDP2-
SIM in mammalian cells, we were unable to detect it through Western blotting of 
transfected cells (Figure 4c). This is specific to the SIM mutation, as wild-type 
TDP2 is expressed and properly detected. Lack of TDP2-SIM expression would 
make it unsuitable for complementation experiments.    
 To fully characterize the TDP2 SUMO interaction, we entered into collabo-
ration with the group of R. Scott Williams, at the NIEHS/NIH in Research Triangle 
Park, North Carolina (USA). The group has crystallized and published several struc-
tures of TDP2.  
Our collaborators solved the crystal structure of the catalytic portion of 
mouse TDP2 (mTDP2cat, amino acids 108-362) interacting with SUMO2 (Figure 5). 
TDP2 has a novel sumo interacting surface that has been named split-SIM. Instead 
of having the described format of four or more adjacent hydrophobic amino acids, 
(see introduction: SUMO-interacting motifs) the TDP2 SIM is comprised of five 
SUMO-binding elements (SBs) in different parts of the protein (denoted as SB1-5) 
that form a novel SUMO interacting surface due to the 3D conformational of the 
protein. Two short β strands (β0 from region SB1, β14 from SB5) form the split-
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SIM, with the C-terminal Leu370 from β14 inserting into the SUMO2 hydrophobic 
binding pocket. Three loops, SB2 (between β4-β5), SB3 (β6-β7), and SB4 (β12-
β13) contribute to the split-SIM core, together forming a relatively large SUMO-
SIM surface. Interestingly, the predicted SIM (290VFDA293 in mouse) is not part of 
the split-SIM.  
   
2. TOP2 is sumoylated in the context of the cleavage complex 
 Because both TOP2α and TOP2β are SUMO modified (see introduction: 
topoisomerases) and TDP2 has a novel split-SIM, we checked if TOP2 is sumoylat-
ed in the context of TOP2ccs. Additionally, there is the possibility that TOP2cc 
sumoylation could have a cross-talk with TDP2 and in some way regulate its func-
tion. To quantify covalent protein-DNA complexes in cells, we used the in vivo 
complex of the enzyme (ICE) assay (Nitiss et al., 2012).  
Figure 5. Overall structure of DNA/
mTDP2cat/SUMO2 complex. A split–SIM 
(burgundy) and three loops (turquoise) posi-
tion a putatively sumoylated protein 40–70Å 
away from the 5′–phosphate of a substrate 
DNA (gray). Courtesy of Matt Schellenberg 
and R. Scott Williams (NIEHS/NIH).  
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The ICE assay is commonly used as a way to quantify TOP2 covalently 
bound to DNA. This assay uses a cesium chloride gradient to separate free proteins 
from proteins covalently bound to DNA, which are pelleted along with free DNA 
(Figure 6). The DNA pellet is resuspended, and equal amounts slot blotted to be 
probed with antibodies specific to either the α or β isoform of TOP2. Since TOP2α 
expression varies during the cell cycle, we removed artifacts due to cell cycle differ-
ences by arresting cells in G0/G1 by confluency and serum starvation.  
We first analyzed the accumulation of TOP2 isoforms in wild-type primary 
MEFs. TOP2βcc were detected upon etoposide treatment (Figure 7). When the pro-
teasome inhibitor MG132 was used to prevent degradation, there was not a signifi-
cant increase in signal as compared to without MG132. Etoposide induced TOP2αcc 
were detected to a lesser extent as compared to TOP2βcc, and also do not have a sig-
nificant increase upon inhibition of the proteasome.  
We reasoned that since sumoylation is a covalent modification, we would be 
able to apply the assay in a novel approach to detect SUMO modified forms of 
Figure 6: Schematic of in vitro complexes of the enzyme assay (ICE). (left) Nuclei contain pro-
teins and DNA. Some of the DNA contains covalently bound proteins such as TOP2. Cells are lysed 
and passed through a cesium chloride gradient. (middle) DNA and DNA with covalently bound pro-
tein is isolated and immunoblotted, (right) and detected with specific antibodies. 
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TOP2cc. The presence of possible SUMO isoforms is confirmed by probing with 
antibodies specific to either SUMO1 or SUMO2/3 (the SUMO2/3 antibody recog-
nizes both SUMO2 and SUMO3 isoforms). With the ICE assay, we were, in fact, 
Figure 7. TOP2cc induced by etoposide are SUMO modified. Representative image and quanti-
fication of a. TOP2α; b. TOP2β; c. SUMO1; or  d. SUMO2/3 covalently bound to genomic DNA 
isolated by ICE in Tdp2+/+ and Tdp2-/- confluency-arrested primary MEFs with or without prior treat-
ment with 100 μM etoposide for 1 h in the presence or absence of 20 μM MG132. Average ± s.e.m.; 
n≥7  
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able to see both etoposide induced SUMO1 and SUMO2/3 signal. Etoposide in-
duced SUMO1 signals decrease dramatically upon inhibition of the proteasome, 
consistent with the observations of Bailey and O’Hare (2005) that upon treatment 
with the proteasome inhibitor MG132, the free SUMO1 pool is depleted. SUMO2/3 
signal does not change upon inhibition of the proteasome. 
Our approach of detecting SUMO signal in TOP2ccs could raise the ques-
tion of whether or not the signal actually corresponds to SUMO modified TOP2, or 
if it could correspond to modification of some other covalently bound protein. The 
first evidence that the SUMO signal corresponds to modified TOP2cc was that the 
signal was etoposide induced. Secondly, we performed Western blots of the ICE 
material, given that slot blotting has the limitation of not being able to resolve pro-
teins by size. Cleavage complexes were micrococcal nuclease digested to remove 
them from DNA and allow separation by SDS-PAGE. Covalent complexes isolated 
from wild-type cells were analyzed and showed that etoposide treatment leads to a 
preferential accumulation of TOP2β and SUMO2/3 signals (Figure 8a). TOP2β mi-
grated at its expected size forming a solid band and a higher molecular weight 
smear. SUMO2/3 signals appeared as a high molecular weight smear colocalizing 
with the smear of TOP2β, suggesting that the SUMO2/3 signal detected in the ICE 
assay corresponds to modification of TOP2β. TOP2α signal was also detected as a 
thin faint concrete band right below TOP2β, but to a much lesser degree than 
TOP2β. SUMO1 was detected as a high molecular weight smear to a lesser extent 
than SUMO2/3. However, the slot blot quantification indicates that the SUMO1 sig-
nal is not weaker than SUMO2. The observation of the presence of unmodified 
TOP2α and TOP2β indicates that only a fraction of TOP2cc are SUMO modified. 
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Figure 8. Full-length TOP2 in TOP2cc is 
SUMO modified. a. Immunoblot of 
TOP2α, TOP2β, SUMO1 and SUMO2/3 in 
whole cell extract (WCE) and covalently 
bound to genomic DNA in confluency- 
arrested primary MEFs following 1 h 100 
μM etoposide treatment (Etop). Samples 
were treated by micrococcal nuclease prior 
to SDS-PAGE to remove covalently linked 
DNA. b. Same is in “a.”, except sample 
was treated with MG132. 
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TOP2α, TOP2β, SUMO1 and SUMO2/3 are all detected in the whole cell extract 
(WCE). The lower molecular weight band that appears below the 55 kDa marker 
corresponds to the micrococcal nuclease digestion buffer which contains BSA. 
Western blot was then performed upon proteasome inhibition (Figure 8b) to confirm 
a lack of SUMO1 upon addition of MG132 that was seen in Figure 7. Only a very 
faint band was seen of SUMO1 that appeared similar in size to the band detected by 
the SUMO2/3 antibody. Finally, we designed an assay to measure TDP2 activity on 
the ICE substrate, and observed that the removal of this signal was dependent on 
TDP2 phosphodiesterase activity, which will be later discussed (Figure 14).  
We then analyzed the accumulation of etoposide induced TOP2αcc and 
TOP2βcc in Tdp2-/- MEFs to see whether or not TDP2 has a role in the metabolism 
of cleavage complexes. Upon treatment with etoposide, TOP2αcc and TOP2βcc 
were detected with similar signal regardless of Tdp2 background. Additionally, up-
on inhibition of the proteasome, levels in Tdp2-/- cells were similar to wild-type 
cells. We then checked if TDP2 has an effect on the sumoylation of TOP2cc. 
SUMO2 signal was induced equally in wild-type and Tdp2-/- cells, and did not differ 
when the proteasome was inhibited. However, we detected more SUMO1 modifica-
tion of covalent complexes in Tdp2-/- background as compared to wild-type.  
 
3. TDP2 binds sumoylated TOP2 
The observation of SUMO modified TOP2cc together with the novel TDP2 
split SIM lead us to wonder if TDP2 is able to interact with sumoylated TOP2. In 
collaboration, the R. Scott Williams laboratory purified TDP2 containing complexes 
by immunoprecipitating YFP-TDP2. Western blotting with corresponding antibod-
ies confirmed TOP2α, TOP2β, and high molecular weight SUMO2/3, revealing that 
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TDP2 associates with covalently modified forms of intact (non-proteolyzed) TOP2 
isoforms (Figure 9a, lanes 4,5).  
Treatment of YFP-TDP2 immunopreciptated (IP) samples with the SUMO 
isopeptidase Ulp1 collapsed TDP2-bound TOP2 protein ladders to a uniformly mi-
grating species, while the OTUB1 deubiquitinase, DNAse I, or alkaline phosphatase 
did not, indicating that TDP2 preferentially interacts with SUMO modified TOP2.  
Intriguingly, IP conducted with an active site variant of TDP2 (H351N) that 
ablates catalytic activity (Schellenberg et al., 2012) was nearly devoid of SUMO2-
TOP2 (Figure 9a, lane 6), indicating that TDP2-bound TOP2-SUMO2 complexes 
derive from TDP2 catalysis that liberates full-length sumoylated TOP2 from the in-
soluble chromatin fraction. Overall, these observations suggested that in addition to 
processing proetolyzed TOP2 fragments (Caldecott et al., 2012; Gao et al., 2014), 
Figure 9. TDP2 binds sumoylated TOP2. a. 
Immunoblotting of soluble cell lysates and IPs 
from cells expressing YFP, YFP-TDP2, or YFP-
TDP2H351N (H-N).  b. Immunoblotting of YFP-
TDP2 IPs after treatment with the indicated en-
zymes. Courtesy of Matt Schellenberg and R. 
Scott Williams (NIEHS/NIH).  
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TDP2 can engage post-translationally marked intact TOP2 molecules. This prompt-
ed us to evaluate the role of TDP2 on non-proteolyzed TOP2cc.  
 
4. TDP2 removes sumoylated TOP2cc 
To confirm the novel function of TDP2 in TOP2cc removal, we first tested 
how proteasome inhibition influences TDP2 function in the repair of chromosomal 
DSBs, by monitoring the resolution of γH2AX foci following etoposide treatment. 
As explained in the introduction, upon induction of a DSB, the highly conserved 
histone variant H2AX is phosphorylated on serine 139, making γH2AX foci a good 
estimate of DSBs. γH2AX foci are induced by etoposide, and upon etoposide re-
moval, we can measure DSB repair by scoring the remaining foci in different condi-
tions or genotypes. Cells were arrested in G0/G1 by confluency and serum starva-
tion. Since the proteasome facilitates conversion of TOP2cc into irreversible DSBs, 
higher doses of etoposide were required to induce quantifiable γH2AX foci in the 
presence of MG132, but they were induced in a dose-dependent manner (Figure 
10a). γH2AX foci were induced in a similar manner in both wild-type and Tdp2-/- 
cells and were similar in appearance to those without proteasome inhibition 
(compare Figure 10b to Figure 10c). 
As previously reported, Tdp2-/- MEFs show reduced efficiency of etoposide-
induced γH2AX foci resolution when compared to wild-type cells, but alternative 
TDP2-independent mechanisms can also operate, leading to a slower repair rate 
(Figure 11ba, Figure 12a). At 3 and 6 hours post-etoposide removal, this difference 
is statistically significant when analyzed by two-way ANOVA with Bonferroni 
posttests with p-values of p<0.001 and p<0.01 respectively.  
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Figure 10. Dose dependent induction of 
γH2AX foci in Tdp2+/+ and Tdp2-/- MEFs. 
a. Quantification and b., c.  representative 
images of γH2AX foci induction after 30 
min etoposide treatment at indicated concen-
trations in absence and presence of pro-
teasome inhibitor MG132 in Tdp2+/+ and 
Tdp2-/- primary MEFs. “a.” is Courtesy of 
Ana M. Muñoz.   
a. 
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In stark contrast, MG132 treatment completely abolished the repair capacity 
of Tdp2-/- cells (Figure 11b, Figure 12b). Since γH2AX foci can be induced post-
etoposide removal, there was even an increase in foci between the time of etoposide 
removal (t = 0) and the repair time points, which have roughly double the number of 
foci. This increase was not seen in wild-type cells, which after 1 hour have the same 
number of foci as t = 0, because the cells had the ability to repair foci even while 
new foci were being induced, and foci were rapidly resolved after that, almost dis-
appearing at 3 hours of repair. Tdp2-/- cells had absolutely no repair even after 6 
hours. This suggests that chromosomal repair of etoposide induced DNA damage 
can still occur in the absence of proteosomal TOP2 degradation in a pathway that 
uniquely requires TDP2 function. The lack of γH2AX foci repair in TDP2-deficient 
background upon proteasome impairment was specific to TOP2 induced damage, as 
Tdp2-/- cells treated with ionizing radiation, which generates heterogeneous DNA 
damage, did not display the same severe repair defect as etoposide (see Figure 32). 
Figure 11. Tdp2-/- MEFs are unable to repair etoposide induced γH2AX foci when the pro-
teasome is inhibited. a. Resolution of γH2AX foci in MEFs at the indicated time post 30 μM etopo-
side exposure. b. As “a.” except with 20 μM MG132 treatment and 200 μM etoposide. Average 
±s.e.m.; n=3; ** p<0.01, *** p<0.001 (two-way ANOVA with Bonferroni post-test).  
RESULTS 
 62 
Figure 12. Tdp2-/- MEFs are unable to repair etoposide induced γH2AX foci when the pro-
teasome is inhibited. a. Representative images of resolution of γH2AX foci in MEFs at the indi-
cated time post- etoposide exposure. b. Same as “a.” except with MG132 treatment. 
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We then monitored the effect of TDP2 on the disappearance of cleavage 
complexes following etoposide removal with the ICE assay. Time points were taken 
at t = 0 (lysis after 1 hour of etoposide treatment), and 15 and 30 minutes post-
etoposide removal. We monitored not only the disappearance of TOP2 signal, but 
also SUMO signal, which corresponded to sumoylated TOP2. 
Figure 13.  Disappearance of TOP2cc and SUMO in Tdp2+/+ and Tdp2-/- MEFs. Representative 
image (top) and quantification (bottom) of a. TOP2α; b. TOP2β; c. SUMO1; or  d. SUMO2/3 cova-
lently bound to genomic DNA in MEFs following 1 h etoposide treatment and recovery for the indi-
cated time at 37 °C in the presence or absence of 20 μM MG132. Average ± s.e.m.; n≥7; *p<0.05 
(two-way ANOVA with Bonferroni post-test).  
a. b. 
c. d. 
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TOP2α signal disappeared at the same rate in both wild-type and Tdp2-/- 
cells, even when the proteasome was inhibited (Figure 13). TOP2β disappearance 
was also independent of Tdp2 background, and the slower disappearance upon inhi-
bition of the proteasome did not reach statistical significance. SUMO2 signal was 
lost at a slower rate in Tdp2-/- cells, but only when the proteasome was inhibited. 
This suggests a function of TDP2 in TOP2cc removal that is independent of the pro-
teasome and facilitated by sumoylation. Interestingly, upon etoposide removal, 
SUMO1 signal, which is induced higher in Tdp2-/- cells, disappeared at the same 
rate regardless of background. A representative image of SUMO1 disappearance 
upon proteasome inhibition is included, but not quantified because of the lack of 
induction at t = 0. The lack of an effect in the disappearance of TOP2β is explained 
by a majority of non-modified cleavage complexes that retain the capacity to direct-
ly revert upon etoposide removal.  
Figure 14. TDP2 removes TOP2 and SUMO from 
cleavage complexes in vitro. a. Representative im-
age of covalently-linked TOP2α, TOP2β, SUMO1, 
and SUMO2/3 removal from DNA following treat-
ment with 10 nM recombinant TDP2. b. Quantifica-
tion of removal of both TOP2β and SUMO2/3 follow-
ing treatment with indicated concentrations of TDP2. 
c. Same as “b.” except with TOP2β and SUMO2/3. 
Average ± s.e.m.; n≥3; p=0.0027 (F-test, exponential 
decay regression).  
a. 
b. c. 
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If TDP2 has an in vivo role in the removal of sumoylated covalent complex-
es, we surmised that we could design an in vitro approach to quantify and confirm 
this removal. To do so, we directly addressed TDP2 in vitro activity on material iso-
lated by the ICE assay, specifically from etoposide treated wild-type primary MEFs. 
Incubation of the ICE material (DNA and covalently bound proteins) with purified 
wild-type TDP2 protein, but not with the TDP2-H135N catalytic mutant, lead to a 
loss in the amount of TOP2α, TOP2β, SUMO1, and SUMO2/3 that remains cova-
lently linked to DNA (Figure 14). The lack of removal with the TDP2-H135N mu-
tant indicated that it was dependent on TDP2 phosphodiesterase activity and ruled 
out the action of contaminant proteases or phosphodiesterases in the protein prepa-
rations. As mentioned above, specific removal of TOP2 and SUMO covalently 
bound to DNA dependent on TDP2 phosphodiesterase activity confirmed that both 
the SUMO1 and SUMO2/3 signals detected in the ICE assay correspond to sumoy-
lated TOP2. The removal was dependent on TDP2 concentration, as adding more 
recombinant protein lead to a decreasing remaining signal. Interestingly, and con-
sistent with the results observed in cells, TDP2 was more efficient in the removal of 
SUMO2/3 than of TOP2β, confirming that TDP2 can directly remove non-degraded 
TOP2 from cleavage complexes and that this can be facilitated by sumoylation by 
SUMO2.  
These observations were unanticipated, as it has been presumed that TDP2 
functionally engages only minimal TOP2 peptides resulting from proteasomal deg-
radation, rather than full-length, post-translationally marked intact TOP2 molecules 
(Caldecott, 2012; Gao et al., 2014). 
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Figure 16. TDP2 binds sumoylated TOP2. a. Immunoblotting of anti-GFP immunoprecipitates 
from cells co-expressing YFP, YFP-TDP2 (wt), or YFP-TDP2-cAE (C-AE) and either non-targeting 
shRNA (nt) or shRNA against ZNF451 (451). b. Coomassie blue stain of “a.” Courtesy of Matt 
Schellenberg and R. Scott Williams (NIEHS/NIH).  
Figure 15. Schematic and expression of constructs 
used in experiments. a. Constructs with wild-type 
full-length TDP2 and TDP2-cAE, a SUMO-interacting 
mutant with a C-terminal AE extension were used. b. 
Immunoblotting of primary Tdp2-/- MEFs infected with 
lentivirus containing indicated constructs. Lane 1 is 
uninfected cells. GFP signal represents infection. 
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5. SUMO interaction is not essential for sumoylated TOP2cc removal 
In order to characterize the role of the Split-SIM, a mutant form of TDP2 
that did not interact with SUMO and that was suitable for complementation assays 
was generated (Figure 15a, TDP2-cAE). By simply adding a C-terminal AE 
(alanine, glutamic acid) extension to the protein, a steric block was created and the 
C-terminal Leu370 could no longer form part of the split-SIM. TDP2-cAE was solu-
ble and expressed in mammalian cells with expression levels similar to TDP2, as 
seen by Western blotting of Tdp2-/- primary MEFs (Figure 15b, lanes 2 and 3). In-
deed, we observed that TDP2-cAE had a diminished interaction with SUMO2 as 
compared to TDP2 (Figure 16a, lanes 1, 3, and 5).  
We first checked if TDP2 interaction with SUMO was important for the re-
moval of TOP2cc. We performed the same in vitro activity assay as previously men-
tioned, but using recombinant TDP2 and TDP2-cAE. TDP2-cAE showed delayed 
kinetics in removing the sumoylated fraction of TOP2 from ICE purified TOP2cc, 
as detected by the slower disappearance of SUMO2/3 signal as compared to wild-
type TDP2. TDP2-cAE had no effect on removal of bulk TOP2β (Figure 17), as an-
alyzed with a nonlinear fit. The TDP2-cAE defect in SUMO removal was specific to 
SUMO2, as SUMO1 signal was removed at the same rate by TDP2-cAE as by 
TDP2. Similar to TOP2β, removal of TOP2α signal was also not affected with the 
TDP2-cAE mutant.  
As a control, we checked TDP2-cAE activity on the removal of tyrosine 
from oligonucleotides in in vitro reactions, to make sure that the differences meas-
ured were not due to an overall difference in 5´tyrosyl DNA phosphodiesterase ac-
tivity. Removal of a covalently bound tyrosine from a 20 nucleotide oligo was rep-
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Figure 17. TDP2-cAE has diminished removal of SUMO modified TOP2. a. TOP2α, b. TOP2β, 
c. SUMO1 and d. SUMO2/3 covalently bound to genomic DNA following in vitro treatment 
with the indicated concentrations of recombinant wild-type (wt) or mutant TDP2 (TDP2-cAE). Av-
erage ± s.e.m.; n≥3; TOP2α p=0.850, TOP2β p=0.912, SUMO1 p=0.181, SUMO2/3 p=0.002 (F-test, 
exponential decay regression).  
Figure 18.  TDP2-cAE has similar 5’TDP activity as compared to TDP2. 5′–TDP activity follow-
ing 1 h incubation of duplex oligonucleotide harboring a terminal 5′–phosphotyrosine moiety with 
the indicated TDP2. Reactions were run on a 20% TBE-urea gel.  
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resented by an increase in electrophoretic mobility on denaturing polyacrylamide 
gels. Comparing size markers (lanes 2 and 1), the higher molecular weight 5´Y 
(oligo with 5´-tryosine) migrates slower than lower molecular weight 5´P (oligo with 
5´-phosphate) (Figure 18). TDP2-cAE had a similar activity on the oligonucleotides 
as wild-type TDP2 protein. This could be seen by partial conversion of 5´Y into 5´P 
with 10 nM protein (lanes 8 and 15) and almost complete conversion at 50 nM 
(lanes 9 and 16). This result indicated that the effect seen on removal of SUMO2 
from ICE material was not due to an overall difference in activity of the proteins. 
 We then checked the cellular repair phenotypes of TDP2 losing its interac-
tion with SUMO. We performed clonogenic survival assays in Tdp2-/- transformed 
MEFs infected with lentivirus overexpressing TDP2 or TDP2-cAE to see if TDP2-
cAE mutant can complement the defect of Tdp2-/- MEFs in clonogenic survival fol-
lowing etoposide treatment, at least under conditions where TDP2 is overexpressed 
(Figure 19a). TDP2 expression lentiviruses were used to infect at a MOI 2.5, and 
etoposide treatment was performed continuously at the indicated concentrations. 
TDP2-cAE was able to fully complement the Tdp2-/- defect, to the same degree as 
complementation with wild-type TDP2.  
We then performed γH2AX repair assays in Tdp2-/- primary MEFs infected 
with the lentiviruses mentioned above. Overexpression of TDP2 caused a significant 
decrease in the number of etoposide induced γH2AX foci as compared to the empty 
vector control (Figure 19b). For this reason, a decreased etoposide dose was used for 
cells infected with the empty vector, and in addition to raw values, repair of foci was 
represented normalized to the induction. TDP2 deletion itself displayed a repair de-
fect (Figure 19c, d), and overexpression of TDP2 in Tdp2-/- cells was able to sup-
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Figure 19.  TDP2-cAE does not have DSB-repair 
defects as measured by  clonogenic survival and 
γH2AX foci resolution. a. Clonogenic survival of 
transformed Tdp2+/+ and Tdp2-/- MEFs complemented 
with lentiviral vectors overexpressing wild-type 
TDP2, TDP2-cAE, or an empty vector control (EV). 
Continuous treatment with the indicated concentra-
tions of etoposide. Average ± s.e.m.; n≥4. b. Induc-
tion of γH2AX foci in confluency-arrested Tdp2-/- 
primary MEFs infected with lentiviral vectors over-
expressing wild-type TDP2 or an empty vector (EV) 
and treated with 30 μM etoposide, c. Resolution of 
γH2AX foci in Tdp2-/- primary MEFs infected with 
lentiviral vectors overexpressing TDP2, TDP2-cAE 
or an empty vector control (EV), following 30 min 
exposure to 30 μM etoposide (15 μM etoposide for 
EV) and the indicated repair time. d. “e.” normalized 
to induction (t = 0). e. same as “d.” except 100 μM 
etoposide and 20 μΜ MG132. Average ± s.e.m.; n=3.  
a. b. 
c. d. 
e. 
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press the defect, as measured by a decrease in γH2AX foci at t = 1 and 3 hours as 
compared to the empty vector. TDP2-cAE was able to complement to the same de-
gree as TDP2 and equally suppress the repair defect of Tdp2-/- MEFs. We then 
checked what would happen in conditions where the proteasome was inhibited with 
the only option for repair being a pathway depending exclusively on TDP2. After 1 
hour of repair, both TDP2 and TDP2-cAE complement the Tdp2-/- cells allowing for 
repair to occur (Figure 19e).  
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7. Role of ZNF451 in cellular response to TOP2 damage 
Additional factors of the cellular sumoylation machinery may be involved in 
regulating the TOP2-SUMO2-TDP2 interaction and TDP2–dependent TOP2cc re-
pair. Performing the BioID screening has opened the door for further analysis of the 
interactions seen with TDP2. One potential candidate is ZNF451.  
Because the BioID protocol identifies even transient proximity-based inter-
actions, we first checked if the interaction detected between TDP2 with ZNF451 
could be confirmed. We pulled down GFP-tagged TDP2 and successfully coim-
munoprecipitated ZNF451 in HEK293T cells (Figure 29). In both the inputs and 
GFP-TDP2 elution, laddering was detected by the ZNF451 antibody, of which the 
upper bands could represent sumoylated forms. This laddering was also seen in 
MEFs and responds to shRNA ZFP451 knockdown, the mouse orthologs of 
ZNF451 (see Figure 31a). 
We checked if ZNF451, like DNA repair proteins, localizes to chromatin 
upon DNA damage, and specifically TOP2 damage. Etoposide treatment in RPE-1 
cells triggered an enrichment of ZNF451 in the chromatin cellular fraction that is 
visible upon proteasome inhibition (Figure 30). Proteasome inhibited etoposide 
treated cells accumulated both unmodified and higher molecular weight forms of 
ZNF451 in the chromatin fraction, likely corresponding to SUMO modified forms. 
Samples were normalized relative to the signal of the untreated sample without 
MG132. ZNF451 mobilization to chromatin was specific to TOP2 damage, and not 
observed following ionizing radiation induced DSBs (Figure 30b).  
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Figure 29. TDP2 interacts with ZNF451. Immunoprecipitation of GFP-tagged human TDP2 and 
GFP with GFP-Trap. Immunoblotting against ZNF451. MW- molecular weight marker. 
Figure 30. ZNF451 is recruited to chromatin upon TOP2 damage and proteasome inhibition. a. 
Representative image of immunoblots (left panel) against ZNF451 in whole-cell extracts (WCE) or 
chromatin fraction of RPE-1 cells upon treatment with and without etoposide and/or MG132. Quanti-
fication (right panel) of ZNF451 levels normalized to the corresponding H3 signal and expressed as 
fold increase compared to the untreated sample. Average ± s.e.m.; n=3; *p<0.05 (two-way ANOVA 
with Bonferroni post-test). b. Same as “a.”, except cells were treated with or without 10 Gy ionizing 
irradiation (IR) in the presence or absence of MG132. Average ± s.e.m.; n=3.  
a. 
b. 
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We then checked the effect of ZNF451 on clonogenic survival following 
continuous etoposide treatment in wild-type cells (Figure 31). As mentioned above, 
ZFP451 knockdown was checked with Western blot, with tubulin as a loading con-
trol (Figure 31a). ZFP451 knockdown did, in fact, decrease cell survival following 
etoposide treatment in wild-type cells (Figure 31b). The shRNA used (ZFP451#2) 
was checked for off target effects by repetition of the clonogenic survival assay with 
a different shRNA (ZFP451 #1). The defect seen in wild-type cells upon ZFP451 
knockdown was reproduced when shRNA ZFP451#1 was used. We then checked 
the effect of ZNF451 in Tdp2-/- cells, and observed that not only did Tdp2-/- itself 
have a strong defect, but upon ZNF451 knockdown, the clonogenic survival defect 
was exacerbated (Figure 31c). Clonogenic survival of both Tdp2+/+ and Tdp2-/- cells 
is represented in Figure 31d. 
Next, we explored the role of ZFP451 in DSB repair, scored by γH2AX foci 
resolution. ZFP451 depletion alone in MEFs did not confer a significant defect in 
γH2AX foci resolution in wild-type cells (Figure 32a). However, in cells with TDP2 
deletion (Tdp2-/-), ZFP451 knockdown caused a significant repair defect. Also, 
ZFP451 depletion caused a delay in the repair kinetics when combined with the pro-
teasome inhibitor MG132 in wild-type cells (Figure 32b). However, Tdp2 deletion 
is epistatic over ZFP451 knockdown when combined with proteasome inhibition, 
conditions where we already had no repair, suggesting that one function of ZFP451 
is to modulate TDP2 dependent TOP2cc repair. Both TDP2 and ZNF451 have a role 
in DSB repair specific to TOP2 damage, as neither TDP2 knockout nor ZNF451 
knockdown had an effect on the resolution of ionizing radiation (IR) induced 
γH2AX foci (Figure 32 c, d).  
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Overall, these results identify ZNF451 as a novel component in the cellular 
response to TOP2-induced damage that operates through both proteasome-
dependent and -independent TOP2cc metabolism, with the latter being dependent on 
TDP2.  
Figure 31. ZNF451 depletion causes a defect 
in clonogenic survival. a. Immunoblotting 
against ZNF451 (top) or tubulin (bottom) of 
MEFs infected with one of two shRNA against 
ZFP451, or with non-targeting shRNA (nt). b. 
Clonogenic survival of transformed wild-type 
MEFs infected with different shRNA for 
ZFP451 or the non-targeting shRNA (nt). Con-
tinuous treatment with the indicated doses of 
etoposide was performed. c. Clonogenic surviv-
al of Tdp2-/- MEF cells following treatment 
with the indicated concentrations of etoposide. 
Average ± s.e.m.; n≥4; *p≤0.05 (F-test, log 
values quadratic regression). d. Representation 
of nt and shRNA ZFP451 #2 of Tdp2+/+ and 
Tdp2-/- from “b.” and “c.” together. 
a. 
b. 
d. 
c. 
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Figure 32. ZNF451 depletion causes a defect in the repair of γH2AX foci induced by etoposide. 
a. Resolution of DSBs mar ked by γH2AX foci in MEF cells post-etoposide exposure at the indicat-
ed repair time in the absence or b. presence of MG132. Average ±s.e.m.; n=3; ns p≥0.05, *p<0.05, ** 
p<0.01 (two-way ANOVA with Bonferroni post-test). c., d. Same as “a.” and “b.” respectively, ex-
cept with ionizing radiaton (IR) treatment. 
a. b. 
d. c. 
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 IV. DISCUSSION 
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IV. DISCUSSION 
 TOP2 is necessary for normal cellular processes, such as DNA replication, 
transcription, and cell division, but it can pose a threat to genome integrity, as the 
intermediate of its catalytic cycle, the enzyme covalently linked to 5’-phosphoryl 
end of a four-base staggered DSB, can interfere with cellular processes and needs to 
be removed in order to allow repair. Therefore, a thorough understanding of how 
TOP2cc are removed is imperative for advancing our understanding of processes 
and functions of TOP2, and furthering possible therapeutic avenues. The identifica-
tion of TDP2 as the enzyme that specifically removes TOP2 from DNA by cleaving 
the 5’-phosphotyrosyl bond was an important advance in the DNA repair field 
(Cortes-Ledesma et al., 2009). TOP2cc in suicidal substrates had to undergo either 
proteolytic processing or denaturation to allow removal by TDP2 (Gao et al., 2014). 
However, whether or not TDP2 would be able to remove full-length TOP2 in vivo 
has remained unknown, and if so, how it would able to access the phosphotyrosyl 
bond between the topoisomerase and the DNA.  
 There have been numerous advances in the field of DNA topoisomerases 
since the discovery of E. coli TOP1 by James C. Wang, starting with biochemical 
studies aiming to elucidate the role in managing DNA topology. The discovery that 
topoisomerases are the targets of medications such as etoposide has been important 
not only in the laboratory, but also for applications such as antimicrobials and can-
cer chemotherapies. Also, the publication of topoisomerase crystal structures has 
aided in understanding of the mechanism. In addition, the resolution of several 
TDP2 crystal structures, such as full-length C. elegans, the catalytic portion of hu-
man TDP2, and the catalytic portion of mouse TDP2-DNA complexes, has provided 
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detailed information on TDP2 catalytic activity (Shi et al., 2012; Hornyak et al., 
2016; Schellenberg et al., 2012). Structural and biochemical work by the Williams 
laboratory provided insight on structural mechanisms of the TDP2 active site 
(Schellenberg et al., 2016). 
 To shed light on the pathways involved in TDP2-mediate removal of 
TOP2cc and its possible regulation, this work has addressed the roles of both 
sumoylation and the novel SUMO E3 ligase ZNF451. A BioID screening opened 
the door for the identification of novel TDP2 interactors that may be involved in this 
process, or indicate additional roles of TDP2. 
 
1. SUMO-modified TOP2cc 
 Upon etoposide treatment, both TOP2αcc and TOP2βcc accumulate in wild- 
type and Tdp2-/- MEFs. TOP2α signal being detected to a lesser degree than TOP2β 
is consistent with the prominent role of the TOP2β isoform in non-proliferating 
cells. Interestingly, etoposide induced TOP2cc are modified by both SUMO1 and 
SUMO2/3.  
 We have several indications that the SUMO2/3 signal corresponds primarily 
to modified TOP2β. Western blotting of micrococcal nuclease digested etoposide 
treated TOP2ccs indicates a high molecular weight smear of TOP2β signal of simi-
lar size to the SUMO2/3 smear, while TOP2α is only present as a non-modified 
band. Additional work done in the Cortés-Ledesma laboratory, such as pulling down 
SUMO2 and detecting TOP2β, indicates that this isoform is preferentially 
SUMO2/3 modified over TOP2α (Schellenberg & Lieberman et al., Science pend-
ing publication). 
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 SUMO2/3 modification of TOP2cc was induced in a similar manner in both 
wild-type and TDP2-defficient cells. However, SUMO1 was induced more-so in 
etoposide treated Tdp2-/- cells than in wild-type cells. One possibility is that TDP2 is 
responsible for the removal of SUMO1 modified full-length TOP2cc. If that were 
the case, we would expect the disappearance of SUMO1 signal to be slower in 
TDP2 deficient cells upon etoposide removal as compared to wild-type cells. This is 
not the case, as the disappearance of SUMO1 signal is no different in wild-type and 
Tdp2-/- cells. Also, while we have observed that TDP2 is responsible for the prefer-
ential removal of SUMO2/3 modified TOP2cc, we do not see an accumulation of 
SUMO2/3-TOP2cc in Tdp2-/- cells, so it is reasonable that an alternative mechanism 
is at play.  
 One attractive scenario is that SUMO1 modification still remains on the pep-
tide resulting from proteasomal degradation of TOP2cc. That would explain why 
there is an accumulation of SUMO1 signal in the absence of TDP2, which would be 
important for the removal of this residual peptide. An increase in proteasome de-
graded TOP2-DNA adducts in Tdp2-/- cells would likely not be able to be measured 
by neither the TOP2α nor TOPβ antibodies, which are specific to the C-terminus. 
The exact identity of the proteasomal product is unknown, although it undoubtedly 
contains the catalytic tyrosine (for example, Tyr805 in H. sapiens TOP2α, Try825 in 
TOP2β).  
 It would be interesting to uncover the identity of the degraded peptide ad-
duct, whether it be a peptide with a specific sequence or a heterogeneous population 
of proteasomal degraded products. When Western blotting micrococcal nuclease 
digested etoposide-induced TOP2cc, the only detectable SUMO1 signal corresponds 
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to high molecular weight TOP2, which would be consistent with it being conjugated 
to full-length or minimally degraded forms. If there is, in fact, a SUMO1 modified 
lower molecular weight degraded TOP2 peptide that we are not detecting, it could 
be that the peptide is heterogeneous in size and/or lowly abundant, below detection 
levels. If that were the case, once again we could expect to see a delayed kinetic in 
the disappearance of SUMO1 signal in the absence of TDP2, which we do not see. 
Another explanation is that SUMO1 signal corresponds to modification of full-
length TOP2cc and for some reason, in the absence of TDP2, there is either in-
creased modification or accumulation of modified forms. In the future, it would be 
interesting to compare the SUMO1 signal in wild-type cells with Tdp2-/- cells by 
Western blot to see if there are additional lower molecular weight SUMO1 conju-
gates in Tdp2-/- cells, although with Western blot the level of detection may not be 
sufficient to discern a difference.  
 We do observe disappearance of SUMO1 signal upon inhibition of the pro-
teasome with MG132 in both genotypes. This is most likely due to depletion of the 
cellular pool of SUMO1, which has been observed to deplete upon MG132 treat-
ment (Bailey & O’Hare, 2005). An alternative possibility is that, in line with the dis-
cussion above, is that SUMO1 modification occurs on the peptide after proteasomal 
degradation. As such, upon inhibiting the proteasome, that signal would disappear. 
However, this is again not consistent with the results observed in the Western blots. 
 The dynamics of SUMO2/3 disappearance in proteasome inhibited Tdp2-/- 
MEFs were the first indication of the role of TOP2cc sumoylation in promoting pro-
teasome-independent TDP2 catalyzed TOP2cc removal. While SUMO2/3 signal 
disappears more slowly in the absence of TDP2, TOP2 does not. There are several 
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plausible explanations for this. We are working with a pools of cells in which not all 
TOP2cc are SUMO modified. This is also explained by the reversion of reversible 
covalent complexes once the etoposide is removed, which could present a majority 
of TOP2cc. To clarify, when etoposide is removed from TOP2, the enzyme can re-
seal the broken DNA within the cleavage complex, a phenomenon termed 
“reversal” (Tewey et al., 1994). 
 However, even when the proteasome is inhibited, there is still not a signifi-
cant increase in the accumulation of neither etoposide induced TOP2αcc nor 
TOP2βcc, even in TDP2-deficient background. This is consistent with the observa-
tions of Austin and colleagues, who reported that proteasome inhibition in K562 cell 
line, human chronic myelogeneous leukemia, did not affect etoposide induced accu-
mulation of TOP2cc (Lee et al., 2016). They used the same dose of etoposide as our 
experiments, although with two hour treatments, and measured TOP2cc with the 
cell-based TARDIS microscopy assay. However, with their conditions, they ob-
served that MG132 treatment reduces the rate of removal of etoposide stabilized 
TOP2cc from DNA. We do indeed see a slower rate of removal of TOP2βcc when 
the proteasome is inhibited in both wild-type and Tdp2-/- cells, although this differ-
ence does not arrive to statistical significance when comparing to conditions without 
MG132.  
 Given the novel role of TDP2 in removing TOP2cc independent from the 
proteasome, one could reason that in Tdp2-/- cells, we could expect a greater accu-
mulation, or at least a slower disappearance of these structures. There are several 
plausible explanations for the lack of such an observation. The high dose and long 
exposure of etoposide could be saturating the number of TOP2cc, preventing the 
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measurement of an increase in TDP2-deficient cells. Also, if only a small portion of 
TOP2cc are sumoylated, and this seems to be the case since in Western blots most 
TOP2 migrates with its expected size, and those could be preferentially targeted by 
TDP2, we would not see a measurable difference in TOP2cc removal when TDP2 is 
not present because the majority are not sumoylated.  
 It would be interesting in the future to address whether or not sumoylation 
itself could affect reversibility of TOP2cc. If SUMO2/3 modified TOP2cc are less 
likely to revert upon etoposide removal, then they would be more dependent on the 
pathways that remove trapped TOP2, such as that involving TDP2, especially when 
the proteasome is inhibited, which is in line with our observations.  
 
2. TDP2 interaction with SUMO  
 The current understanding of what constitutes a SIM will be updated upon 
the identification of a nonconventional novel SUMO-interacting surface by our col-
laborators in the R. Scott Williams laboratory. Instead of four or five consecutive 
amino acids, the TDP2 split-SIM is comprised of SUMO binding loops. The SIM-
SUMO interface is relatively large, giving TDP2 strong SUMO2 binding.   
 While the 280IVDV283 sequence of human TDP2 is not contained within the 
newly identified split-SIM, phenotypes of mutating this putative SIM identified by 
Hecker et al. (2006) have been reported. For example, nucleolar localization of 
TDP2 was described as requiring binding to PML-NBs through the 280IVDV283 SIM 
(Vilotti et al., 2011). Silencing TDP2 expression during proteasome impairment 
causes alterations in rRNA biogenesis, namely a decrease in pre-rRNA and an accu-
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mulation of processing intermediates. The TDP2 SIM motif, but not TDP2 catalytic 
activity, has an important for role in ribosome biogenesis.  
 TDP2 280IVDV283 is likely not a bona fide SIM, although when mutated, it 
abolishes SUMO interactions. One possibility is that the mutation of 280IVDV283 to 
alanines could alter the conformation of the protein and affect the interactions with 
at least SUMO. Notably, we were unable to express TDP2-SIM, our version of 
280AAAA283, in human cells.  
 Another possibility is that 280IVDV283 acts as an additional SIM. However, 
this was not observed by crystallization of TDP2 interacting with SUMO2. It would 
be interesting to take another look at the phenotypes of 280AAAA283, such as ribo-
some biogenesis, to see if they are recapitulated with split-SIM mutant TDP2-cAE. 
If they are not, it could be possible that role of TDP2 in ribosome biogenesis is re-
lated to interaction with protein(s) other than SUMO, that were abolished upon mu-
tating 280IVDV283. 
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3. TDP2 removal of TOP2cc mediated by ZNF451 
 One of the most impacting results of this thesis is the discovery of a role of 
TDP2 in a novel proteasome-independent pathway for the removal of TOP2cc. 
There are several convincing evidences for the existence of such a pathway. First is 
the inability of alternative pathways to repair etoposide-induced DSBs upon pro-
teasome inhibition in Tdp2-/- cells. This indicates that TDP2 is uniquely important to 
remove undegraded TOP2. Perhaps in this proteasome-independent pathway, DNA 
repair factors such as KU are unable to bind the break region of the DNA due to ste-
ric interference with TOP2 until this is removed by TDP2. This would not occur 
when TOP2 is degraded by the proteasome. 
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 Second, the interaction of TDP2 with SUMO-TOP2 is completely dependent 
on  its phosphodiesterase activity, suggesting that it arises as a result of TDP2 action 
on sumoylated cleavage complexes. Third, as mentioned above, in Tdp2-/- cells 
SUMO2/3 signal disappears slower. Finally, TDP2 has an in vitro activity on 
TOP2cc, showing a preference for SUMO-modified TOP2cc. Denaturing of cova-
lent complexes on DNA has been reported to be sufficient to allow hydrolysis by 
TDP2, and the cleavage complexes on DNA isolated in the ICE protocol were de-
naturated by the initial cellular lysis with N-Lauroylsarcosine sodium salt 
(sarkosyl). 
 While TDP2 removes TOP2cc in vitro, a mechanism that would allow TDP2 
to access the phosphotyrosyl bond of full-length TOP2 in cleavage complexes in 
vivo has not been previously reported. In the pending manuscript, the Scott Williams 
laboratory  detected very little TDP2 activity on non-denatured reconstituted 
TOP2cc in vitro (Schellenberg & Lieberman et al., Science accepted). However, we 
do see a role in vivo, suggesting mechanisms that make covalent complexes accessi-
ble for TDP2. There are several evidences that the novel E3 SUMO2 ligase ZNF451 
might regulate proteasome-independent mechanisms for TOP2 removal, which are 
addressed in this thesis and pending manuscript. First, we observed that TDP2 and 
ZNF451 interact and ZNF451 is mobilized to chromatin upon TOP2 damage. It was 
then observed that TDP2 has novel split-SIM that interacts strongly with SUMO2, 
and both TDP2 and ZNF451 are bound to sumoylated TOP2. It was observed that 
recombinant ZNF451 forms a stable complex with purified TOP2α and TOP2β, by 
analytical gel filtration chromatography in the accepted manuscript (Schellenberg & 
Lieberman et al., Science pending publication). Additionally, upon addition of 
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Figure D1. Proposed Model for resolution of abortive TOP2cc. For simplicity, only G-segment 
is shown. Proposed model for TDP2 removal of abortive TOP2cc (purple) comprised of full-length 
TOP2. TOP2 covalently linked to 5’ termini by phosphotyrosyl bond between tyrosine in the protein 
and phosphate of DNA is SUMO modified (green) and is either partially degraded by the proteasome 
leaving a peptide of unknown size, or is removed in a proteasome independent pathway which in-
volves TDP2 and ZNF451 acting on full-length TOP2 and can be modulated by the sumoylation of 
TOP2. Nucleolytic pathways are not shown for simplicity. P- phosphate, Y- tyrosine, OH- hydroxide, 
S-SUMO2/3. 
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ZNF451, TDP2 had dramatically increased activity on non-denatured reconstituted 
TOP2βcc. To get insights into the mechanism by which ZNF451 is able to remodel 
TOP2cc to allow TDP2 access to the buried phosphotyrosyl bond, trypsin digest 
sensitivity of TOP2cc in the presence and absence of ZNF451 was measured. The 
data suggests that ZNF451 induces a conformational change in both TOP2αcc and 
TOPβcc. 
 Not surprisingly, ZNF451 was observed to regulate TOP2 sumoylation. 
When the effect of sumoylation on TDP2-catalyzed TOP2cc resolution was exam-
ined, it was found that sumoylation promoted only a minimal increase in TOP2cc 
hydrolysis by TDP2 over and above the ZNF451–TDP2 catalyzed reaction. Sumoy-
lation of TOP2cc is therefore more likely aiding with the recruitment of TDP2 ra-
ther than directly affecting its 5’-phosphodiesterase activity.  
Therefore, we propose a model for TDP2 mediated removal of TOP2cc 
(Figure D1). In our model, in addition to removal of proteasome degraded TOP2 
adduct by TDP2 (or nucleases), there is an additional proteasome-independent path-
way, which is entirely dependent on TDP2. ZNF451 mediated remodeling and 
sumoylation of TOP2cc would facilitate the recruitment of TDP2 and its access to 
the otherwise hidden phosphotyrosine bond.  
 The action of ZNF451 is likely regulated, as to not interfere with active 
TOP2 during the normal catalytic cycle, and mechanisms for its regulation have not 
yet been uncovered. Also, there is a possibility that ZNF451 action could affect re-
versibility of TOP2cc. Once bound to TOP2cc, poised for TDP2 cleavage, TOP2 is 
likely rendered unable to revert. Contrarily, ZNF451 could be targeting those 
TOP2cc that are already unable to revert. Moreover, the existence of this new pro-
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teasome-independent pathway opens the door to the study of possible regulatory 
methods for pathway choice, that is, which TOP2cc are degraded by proteasome and 
which are removed by the novel pathway, whether the signal be sumoylation or not.  
 While ZNF451 has been identified as an E3 SUMO ligase responsible for 
SUMO2/3 conjugation of TOP2 in the context of the covalent complex, the E3 en-
zyme responsible for SUMO1 conjugation has not been addressed in this study. 
RANBP2 has been implicated in SUMO1 modification of TOP2α and could be a 
possible candidate. Very recently, work by Sun and Nitiss implied a role for sumoy-
lation of TOP2cc in yeast by the Siz1 SUMO ligase (Sun & Nitiss, 2017). It would 
be interesting to test whether or not the homologous members of the PIAS family 
play a similar role in human cells. 
  
DISCUSSION 
 107 
DISCUSSION 
 108 
  
5. TDP2, TOP2, and human diseases  
The discovery of a TDP2-dependent pathway for the removal of full-length 
TOP2cc offers an additional therapeutic target route for potential TDP2 inhibitors. 
There is significant variation of TDP2 expression among cancer patients, limiting 
the success of TOP2 poisons as a treatment (Kont et al., 2016). This opens the door 
for individualized treatment of the patients with high TDP2 levels with TDP2 inhib-
itors in conjunction with TOP2 inhibitors. Additionally, Schellenberg and col-
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leagues (2016) identified a TDP2 active site single nucleotide polymorphism (SNP) 
D350N that impairs TDP activity. TDP2 status could serve as a biomarker for per-
sonalized medicine.  
Clinical use of TDP2 as a pharmacological target also stems from TDP2 
knockout cells being highly sensitive to TOP2 poisons (Cortes-Ledesma et al., 
2009). Additionally, as TDP2 serves as a backup form of repair in absence of TDP1 
upon treatment with TOP1 inhibitors such as camptothecin, it might be useful for 
the treatment of certain lung cancers which are deficient for TDP1 (Gao et al., 
2014). The combined use of TDP2 and TOP2 inhibitors could also be applied to pa-
tients with ATM or HR deficiencies, which occur frequently in cancers (Choi et al., 
2016). TDP2 inhibitors may also further the study of the role of TDP2 in viral repli-
cation/integration and offer the possibility of generating novel antiviral compounds 
targeting it. A high throughput screening identified Toxoflavins and Dezaflavins as 
the first selective small molecule inhibitors of TDP2, but are of little pharmaceutical 
value due to poor in vitro pharmacokinetics profiles and low cell permeability, re-
spectively (Raoof et al., 2013).  
 Major challenges of treatment with TOP2 poisons include toxicity, re-
sistance, and secondary malignancies. A main goal of TOP2 cancer treatments is 
therefore maximization of clinical efficacy while minimizing toxicity and secondary 
malignancies (Nitiss, 2009a). TOP2 poisons generally have limited tumor selectivity 
and toxicity rooted in the need of TOP2 in normal cells, not only cancer cells. Part 
of the sensitivity to TOP2 targeting drugs depends on TOP2 protein levels. Most 
TOP2 targeting drugs kill cells by generating TOP2-mediated DNA damage. Cellu-
lar resistance to TOP2 poisons is generally related to decreased levels of TOP2 ex-
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pression, and therefore generation of less TOP2-mediated DNA damage (Walker & 
Nitiss, 2002). On the other hand, elevated TOP2 levels render the cell hypersensi-
tive to the poisons but resistant to inhibitors, as inhibitors and poisons are usually 
antagonistic. Catalytic inhibition of the enzyme is an alternative strategy to treat-
ment with TOP2 poisons, although currently lack of potency is an issue, new inhibi-
tors are being developed. 
Because of its novel role in the cellular response to TOP2 damage, it would 
be useful to look into the possibility of the use of therapeutic ZNF451 inhibitors. 
Perhaps, if TDP2 and ZNF451 inhibitors were to be used in combination with 
etoposide, etoposide doses could be lessened, and therefore possibly decrease side 
effects of etoposide treatment. Additionally, in tumors where there are low TOP2 
levels, it would be interesting to study the combination of TOP2, ZNF451, and 
TDP2 inhibitors.  
 
6. Future work 
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V. CONCLUSIONS 
1. TDP2 binds SUMO through a novel split-SIM independently from the previous-
ly described 280I-V-D-V283 SIM. 
2. SUMO1- and SUMO2/3-modified TOP2cc accumulate in response to etoposide 
in primary MEFs. 
3. Proteasome inhibition does not increase accumulation of TOP2cc in response to 
etoposide, nor their SUMO2/3 modification, but it abolishes modification by 
SUMO1. 
4. The absence of TDP2 does not affect accumulation of TOP2cc in response to 
etoposide, but it increases sumoylation specifically by the SUMO1 isoform. 
5. TDP2 facilitates removal of undegraded SUMO2/3 modified TOP2cc in vitro 
and in vivo, and this is facilitated by TDP2-SUMO interactions mediated by the 
TDP2 split-SIM. 
6. In conditions of proteasome inhibition, repair of TOP2-induced DSBs is com-
pletely dependent on TDP2. 
7. ZNF451 is involved in the response to TOP2-induced DNA damage by both 
TDP2 dependent and independent pathways. 
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1. Cell culture procedures  
 
1.1. Cell lines and primary cell culture  
 Cells in culture were maintained in HEPA class 100 incubators (Thermo) at 
37 C in 5% CO2 unless otherwise indicated. All media was supplemented with 50 
U μL-1 penicillin and 50 μg mL-1 streptomycin. 
 Primary MEFs were isolated from embryos at day 13 p.c. and cultured at 3% 
O2 in Dubelcco’s Modified Eagle’s Medium (DMEM) supplemented with 2 mM L-
Glutamine, 15% Fetal Bovine Serum (FBS) and non-essential amino acids. All ex-
periments were carried out between P1 and P4.  
 Transformed MEFs were maintained in DMEM supplemented with 2 mM L-
Glutamine and 10% FBS. MEFs were transformed by retroviral delivery of T121, a 
fragment of the SV40 large T antigen that antagonizes the three Rb family members 
but not p53 (Saenz Robles et al., 1994). After several passages under puromycin se-
lection, clones that efficiently grew were selected.  
 HEK293T and U2OS cells were maintained at 37°C, 5% CO2 in DMEM 
supplemented with penicillin, streptomycin, 2 mM L-Glutamine and 10% FBS.  
 RPE-1 cells were maintained at 37°C, 5% CO2 in F12 media with L-
Glutamine (Sigma) supplemented with penicillin, streptomycin and 10% FBS.  
 
1.2. Lentiviral production, titration, and infection  
 Lentiviral particles were either produced or purchased from the Viral Vector 
unit of the Spanish National Center for Cardiovascular Research (CNIC). To pro-
duce lentiviral particles in house, 6.9x106 HEK293T cells were grown in 150 mm 
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plates and transfected by a calcium/phosphate protocol with a mixture composed of 
38.4 μg of the lentiviral vector of interest, 25.6 μg of p8.91 (plasmid containing vi-
ral capsid genes) and 12.8 μg of pVSVG (plasmid containing viral envelope genes). 
Medium was changed 19 h after transfection, then particles were recovered 48 h lat-
er and filtered through a 0.45 μm polypropylene filter (10462100, Whatman: GE 
Healthcare). Viral particles were concentrated by centrifugation for 1.5 h at 22,000 
rpm at 4C in a Beckman-Coulter Optima L-100K Ultracentrifuge and resuspended 
in ice cold DMEM, aliquoted and stored at -80 C.  
 For titration of shRNA-ZNF451, RPE-1 cells were infected with serial dilu-
tions of lentiviral particles. After 72 h, qPCR was performed detecting lentiviral in-
tegration with oligonucleotides for the long terminal repeat (LTR). Values were nor-
malized to Albumin (number of cells), and to the standard curve of oligonucleotides 
to correct for primer efficiency. Western blot confirming knockdown was performed 
in the cell type to be used for experiments. 
 Titer of GFP expressing lentivirus was calculated using BD FACSCalibur 
Flow Cytometer (342975, BD Biosciences) and measuring GFP expression in cells 
infected with serial dilutions of lentiviral particles.  
 Overexpression of TDP2 was carried out by lentiviral infection at MOI 2.5, 
and confirmed by western blot. For shRNA depletion, cells were infected with equal 
amounts, as determined by qPCR titer, of non-targeting and ZFP451 shRNA lentivi-
ral particles followed by 10-day selection in 2μg mL-1 puromycin to obtain at least 
80% knock-down efficiency.  
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2. Molecular and cell biology procedures  
2.1. γH2AX foci analysis and Immunofluorescence 
 Primary MEFs were grown on coverslips for 7 days until confluency arrest, 
followed by 3 day serum starvation in DMEM supplemented with 0.5% FBS. Cells 
with shRNA depletion (and non-targeting controls) were not serum starved. Cells 
were pretreated with 20 μM MG132 or vehicle (DMSO) for 1.5 h then treated with 
30 μM etoposide (MG132 free samples) or 200 μM etoposide and 20 μM MG132 
for 30 minutes, then fixed in ice-cold methanol for 10 min at -20°C.  
 Immunofluorescence was carried out as described (Alvarez-Quilon et al., 
2014). Briefly, cells were permeabilized (2 min in PBS-0.2% (v/v) Triton X-100), 
blocked (30 min in PBS-5% (w/v) BSA) and incubated with the primary antibody 
for 1 h in PBS-1% (w/v) BSA. Cells were then washed (three times in PBS-0.1% (v/
v) TWEEN 20), incubated with the secondary antibody for 30 min in 1% (w/v) BSA
-PBS, washed again as described above, counterstained with DAPI (Sigma) for 2 
min, and mounted in Vectashield (Vector Labs). γH2AX foci were manually count-
ed (blind) in 40 cells for each experimental condition with a Leica DM6000B mi-
croscope with the 100X oil objective. Statistical analysis with two-way ANOVA 
with Bonferroni post-test was performed.  
 
2.2. Chromatin fractionation 
 Serum-starvation arrested RPE-1 cells were pretreated for 1.5 h with 20 μM 
MG132 or vehicle (DMSO), then 1 h with 100 μM etoposide or vehicle (DMSO), 
and processed as described (Ochi 2015). Briefly, cells were washed twice in ice-
cold PBS, and pre-extracted twice for 3 min on ice in CSK buffer (100 mM NaCl, 
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300 mM sucrose, 3 mM MgCl2, 0.7% (v/v) Triton X-100, 10 mM PIPES, pH 7.0). 
After pre-extraction, cells were washed 3 times in ice-cold PBS and harvested in 
SDS loading buffer. Samples were run in 4-20% precast polyacrylamide gels 
(Biorad) and transferred/incubated as described above.  
 
2.3. TDP2 Purification 
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2.4. BioID 
 
2.5. ICE assay 
 Confluency arrested primary MEFs were pretreated for 1.5 h with 20 μM 
MG132 or vehicle (DMSO) followed by 100 μM etoposide (Sigma E1383) or vehi-
cle (DMSO) for 1 hour. They were either immediately lysed in 1% (w/v) sarkosyl 
(Sigma L7414) or washed twice with PBS and incubated at 37 °C in fresh media for 
the indicated times before lysis. Lysates were processed according to the in vivo 
complex of enzyme (ICE) assay (Nitiss et al., 2012). Briefly, sheared samples were 
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centrifuged with a CsCl (Applichem-Panreac, A1098) gradient at 57,000 r.p.m. for 
20 h at 25 °C using 3.3 ml 13 x 33 mm polyallomer Optiseal tubes (Beckman Coul-
ter) in a TLN100 rotor (Beckman Coulter) in an Optima MAX ultracentrifuge 
(Beckman Coulter).  
 For slot blotting, ICE samples containing 5 μg of DNA were transferred onto 
Odyssey Nitrocellulose Membranes (LI-COR Biosciences) using a Bio-Dot SF Mi-
crofiltration Apparatus (Biorad). For western blot of ICE, samples were resuspended 
in 12,000 units of Micrococcal Nuclease (NEB, M0247S), 1x micrococcal nuclease 
buffer (NEB, B0247S) and 100 μg mL-1 BSA (NEB, B9000S), then incubated at 37 
°C for 6 h. Samples were run in 10% SDS-PAGE and transferred to Immobilon-FL 
Transfer Membranes (Millipore). Membranes were blocked for 1 h in Odyssey 
MATERIALS AND METHODS 
128  
Blocking Buffer (LI-COR Biosciences), then incubated for 2 h with primary anti-
bodies in the same buffer with additional 0.1% (v/v) TWEEN 20, washed 3x with 
TBS-0.1%-TWEEN20, incubated with secondary antibodies for 1 h, and finally 
washed again. Once the membranes were dry, slots were analyzed and quantified in 
Odyssey CLx using ImageStudio Odyssey CLx Software.  
 
2.6. In vitro TDP2 activity on ICE-isolated TOP2-DNA crosslinks 
 TOP2-DNA crosslinks were isolated as described above and resuspended in 
bi-distilled H2O. Samples containing 20 μg of DNA were incubated in reaction buff-
er (50 mM Tris-HCl pH 7.5, 50 mM KCl, 1 mM DTT, 100 μg mL-1 BSA, 1mM 
MgCl2) with the given concentration of TDP2 in a total volume of 300 μl for 1 h at 
37°C. Reactions were stopped by the addition of 600 μL STOP buffer (50mM 
EDTA, 1% (w/v) Sarcosyl) and placed on ice. Samples were centrifuged a second 
time according to the ICE assay, and 5 μg of DNA was used in a slot blot. Statistical 
analysis was performed with F-test, exponential decay regression. 
 
2.7. In vitro 5’-TDP activity on oligonucleotides 
 Assays of 5′–Tyrosyl DNA phosphodiesterase activity on synthetic 5′–
phosphotyrosine DNA oligonucleotides were performed as previously described 
(Cortes-Ledesma et al., 2009). Substrates were generated by mixing the appropriate 
40 pmoles of 5’ phosphotyrosine and 20 pmoles of reverse complementary. They 
were mixed in a total volume of 30 μL, and annealed by heated to 95 C for 10 min, 
and cooled down for 10 min at each of the following temperatures: 70C, 45C, 20
C, and 4C.  
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 Annealed DNA duplexes were labeled by incubation with Klenow polymer-
ase (Takara) for 1 h at 37 C in the presence of [α-32P]-dCTP and 50 μM ddTTP. 
Unincorporated [α-32P]- dCTP was removed by Illustra MicroSpin G-25 Columns 
(GE Healthcare). Reactions contained 50 nM substrate, 80 μM competitor single-
stranded oligonucleotide and the indicated amount of recombinant protein in a total 
volume of 6 μL Reaction Buffer (50 mM Tris-Cl, pH 7.5, 50 mM KCl, 1 mM 
MgCl2, 1 mM DTT, 100 μg ml
-1 BSA).  
 Reactions were stopped by the addition of Formamide Loading Buffer and 
boiling for 5 min at 95 °C. Samples were resolved in 7 M Urea denaturing 20% pol-
yacrylamide gel electrophoresis in 0.5x TBE buffer. Gels were analyzed by phos-
phorimaging in a Fujifilm FLA5100 device (GE Healthcare).  
 
2.8. Clonogenic survival assays 
 Clonogenic survival assays were carried out by seeding T121 transformed 
MEFs in 100 mm dishes in duplicate for each experimental condition. To compen-
sate for growth defects, 4,000 cells were seeded for Tdp2+/+ cells and 20,000- 
50,000 cells for Tdp2-/-. After 6 h, the indicated concentration of etoposide was add-
ed and cells were incubated for 10–12 days. Dishes were fixed and stained for man-
ual colony counting in Crystal Violet solution (0.5% (w/v) Crystal Violet in 20% 
v) ethanol). The surviving fraction at each dose was calculated by dividing the aver-
age number of visible colonies in treated versus untreated dishes, relative to the 
number of seeded cells.  
 
2.9. Site-directed Mutagenesis 
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 Amino acid substitutions were performed by limited polymerase chain reac-
tion amplification of plasmid DNA using KOD hot-start DNA polymerase and oli-
gonucleotides containing the mutated codons, followed by digestion of remaining 
input plasmid DNA using the methylation sensitive enzyme DpnI (New England 
Biolabs). 
 
2.10 .Yeast Two-Hybrid Assay (Y2H) 
 To check interactions between TDP2 and SUMO, a yeast two-hybrid assay 
(Y2H) was performed. A standard rapid yeast transformation protocol was used. A 
GAL4 based Y2H system was used, with TDP2 cloned into the bait vector 
pGBKT7, and SUMO1 and SUMO2 cloned into the prey pACT. The strain Y190 
(see table 2 for genotype) was used. Growth on –leucine/-tryptophan plates indicat-
ed successful transformation of both plasmids while growth on –leucine/-
tryptophan/-histidine plates represented interaction. 3-Amino-1,2,4-triazole (3-AT), 
a competitive inhibitor of the product of the HIS3 gene, was added to -histidine 
plates to remove background growth. 5x serial dilution drops were plated.  
 Non-conjugatable SUMO1 and 2 were a gift from Mario Garcia, in the 
pLEXA vector. They were cotransformed with TDP2 in the pACT vector, and the 
LexA system was used. Strain NMY51 was used (see table 2 for genotype).  
 
2.11. GFP pulldown 
 Pulldown of GFP-tagged proteins was performed with GFP-Trap 
(Chromotek) following the manufacturer instructions. 
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2.12. His-tag pulldown 
  
 
MATERIALS AND METHODS 
132  
Cell name  Species  Origin  
Primary MEFs  Mus musculus Embryonic fibroblasts 
Transformed MEFs  Mus musculus  SV40-transformed embryonic fibroblasts  
HEK293T  Homo sapiens  Embryonic kidney transformed cell line  
U2OS  Homo sapiens  Osteosarcoma cell line  
RPE-1 Homo sapiens  Retinal pigmented epitelial cells 
NIH 3T3 Mus musculus  Fibroblast 
HeLa Homo sapiens Cervical cancer 
A549 Homo sapiens 
Adenocarcinomic human alveolar basal epithelial 
cells 
Primary Antibody Working Dilution Source Species 
GFP 1/3,000 Roche, 11814460001 Mouse 
Histone H3 1/3,000 Abcam, ab1791 Rabbit 
SUMO1 1/200, 1/500 DSHB Mouse 
SUMO2 1/500, 1/1,000 Santa Cruz, sc-32873 Rabbit 
TDP2 1/1,000 Gift from Keith Caldecott Rabbit 
TOP2α 1/1,000, 1/3,000 Santa Cruz, sc-365916 Mouse 
TOP2β 1/1,000 Santa Cruz, sc-13059 Rabbit 
Tubulin 1/15,000 Sigma,T9026  Mouse 
ZNF451 1/500, 1/1,000 SAB2102880, 108741 Rabbit 
γH2AX 1/1,000 Millipore, 05-636 Mouse 
Secondary antibody  Working Dilution Source 
IRDye 680RD goat anti-mouse IgG (H+L) 1/10,000  LI-COR 
IRDye 800RD goat anti-rabbit IgG (H+L) 1/10,000  LI-COR 
Goat anti-mouse-AlexaFluor488  1/1,000 ThermoFisher 
Goat anti-mouse-AlexaFluor594 1/1,000 ThermoFisher 
Rabbit IgG/heavy and light chain cross absorbed Cy3 1/1,000 Bethyl Laboratories 
Table M1: Cells used in this Thesis.  
Table M3: Secondary antibodies used in this study 
Table M2: Primary antibodies used in this study 
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Strain Genotype 
Y190 
MATa, ura3-52, his3-200, ade2-101, lys2-801, trp1-901, leu2-3, 112, 
gal4Δ, gal80Δ, cyhr2, LYS2 : : GAL1UAS-HIS3TATA-HIS3, MEL1 URA3 : 
: GAL1UAS-GAL1TATA-lacZ  
NMY51 
MATa, his3Δ200, trp1–901, leu2–3 112, ade2, LYS2::(lexAop)4-HIS3, 
ura3::(lexAop)8-lacZ, ade2::(lexAop)8-ADE2 GAL4 
Table M4: Yeast used in this study 
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